


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :  C12N 15/13, C07K 16/46, 17/00, A61K 39/395		A1	(11) International Publication Number: WO 96/27011  (43) International Publication Date: 6 September 1996 (06.09.96)
(21) International Application Number: PCT/US96/01598			(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 5 February 1996 (05.02.96)			
(30) Priority Data: 08/399,106 1 March 1995 (01.03.95) US			
(71) Applicant: GENENTECH, INC. [US/US]; 460 Point San Bruno Boulevard, South San Francisco, CA 94080-4990 (US).			Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(72) Inventors: CARTER, Paul, J.; 2074 18th Avenue, San Francisco, CA 94116 (US). PRESTA, Leonard, G.; 1900 Gough Street #206, San Francisco, CA 94109 (US). RIDGWAY, John, B.; 821 Diamond Street #1, San Francisco, CA 94114 (US).			
(74) Agents: LEE, Wendy, M. et al.; Genentech, Inc., 460 Point San Bruno Boulevard, South San Francisco, CA 94080-4990 (US).			

**(54) Title: A METHOD FOR MAKING HETEROMULTIMERIC POLYPEPTIDES**



**(57) Abstract**

The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves introducing a protuberance at the interface of a first polypeptide and a corresponding cavity in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heteromultimer formation and hinder homomultimer formation. "Protuberances" are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). The protuberance and cavity can be made by synthetic means such as altering the nucleic acid encoding the polypeptides or by peptide synthesis.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**A METHOD FOR MAKING HETEROMULTIMERIC POLYPEPTIDES****BACKGROUND OF THE INVENTION****Field of the Invention**

This invention relates to a method for making heteromultimeric polypeptides such as multispecific antibodies (e.g. bispecific antibodies), multispecific immunoadhesins (e.g. bispecific immunoadhesins) as well as antibody-immunoadhesin chimeras and the heteromultimeric polypeptides made using the method.

**Description of Related Art****10 Bispecific antibodies**

Bispecific antibodies (BsAbs) which have binding specificities for at least two different antigens have significant potential in a wide range of clinical applications as targeting agents for *in vitro* and *in vivo* immunodiagnosis and therapy, and for diagnostic immunoassays.

15 In the diagnostic areas, bispecific antibodies have been very useful in probing the functional properties of cell surface molecules and in defining the ability of the different Fc receptors to mediate cytotoxicity (Fanger et al., *Crit. Rev. Immunol.* 12:101-124 [1992]). Nolan et al., *Biochem. Biophys. Acta.* 1040:1-11 (1990) describe other diagnostic 20 applications for BsAbs. In particular, BsAbs can be constructed to immobilize enzymes for use in enzyme immunoassays. To achieve this, one arm of the BsAb can be designed to bind to a specific epitope on the enzyme so that binding does not cause enzyme inhibition, the other arm of the BsAb binds to the immobilizing matrix ensuring a high enzyme density at the 25 desired site. Examples of such diagnostic BsAbs include the rabbit anti-IgG/anti-ferritin BsAb described by Hammerling et al., *J. Exp. Med.* 128:1461-1473 (1968) which was used to locate surface antigens. BsAbs having binding specificities for horse radish peroxidase (HRP) as well as a hormone have also been developed. Another potential immunochemical 30 application for BsAbs involves their use in two-site immunoassays. For example, two BsAbs are produced binding to two separate epitopes on the analyte protein - one BsAb binds the complex to an insoluble matrix, the other binds an indicator enzyme (see Nolan et al., *supra*).

Bispecific antibodies can also be used for *in vitro* or *in vivo* 35 immunodiagnosis of various diseases such as cancer (Songsivilai et al., *Clin. Exp. Immunol.* 79:315 [1990]). To facilitate this diagnostic use of the BsAb, one arm of the BsAb can bind a tumor associated antigen and the other arm can bind a detectable marker such as a chelator which tightly binds a radionuclide. Using this approach, Le Doussal et al. made a BsAb 40 useful for radioimmunodetection of colorectal and thyroid carcinomas which had one arm which bound a carcinoembryonic antigen (CEA) and another arm which bound diethylenetriaminepentacetic acid (DPTA). See Le Doussal et al., *Int. J. Cancer Suppl.* 7:58-62 (1992) and Le Doussal et al., *J. Nucl.*

Med. 34:1662-1671 (1993). Stickney et al. similarly describe a strategy for detecting colorectal cancers expressing CEA using radioimmunodetection. These investigators describe a BsAb which binds CEA as well as hydroxyethylthiourea-benzyl-EDTA (EOTUBE). See Stickney et al., Cancer Res. 51:6650-6655 (1991).

Bispecific antibodies can also be used for human therapy in redirected cytotoxicity by providing one arm which binds a target (e.g. pathogen or tumor cell) and another arm which binds a cytotoxic trigger molecule, such as the T-cell receptor or the Fc $\gamma$  receptor. Accordingly, bispecific antibodies can be used to direct a patient's cellular immune defense mechanisms specifically to the tumor cell or infectious agent. Using this strategy, it has been demonstrated that bispecific antibodies which bind to the Fc $\gamma$ RIII (i.e. CD16) can mediate tumor cell killing by natural killer (NK) cell/large granular lymphocyte (LGL) cells in vitro and are effective in preventing tumor growth in vivo. Segal et al., Chem. Immunol. 47:179 (1989) and Segal et al., Biologic Therapy of Cancer 2(4) DeVita et al. eds. J.B. Lippincott, Philadelphia (1992) p. 1. Similarly, a bispecific antibody having one arm which binds Fc $\gamma$ RIII and another which binds to the HER2 receptor has been developed for therapy of ovarian and breast tumors that overexpress the HER2 antigen. (Hseih-Ma et al. Cancer Research 52:6832-6839 [1992] and Weiner et al. Cancer Research 53:94-100 [1993]). Bispecific antibodies can also mediate killing by T cells. Normally, the bispecific antibodies link the CD3 complex on T cells to a tumor-associated antigen. A fully humanized F(ab'), BsAb consisting of anti-CD3 linked to anti-p185<sup>HER2</sup> has been used to target T cells to kill tumor cells overexpressing the HER2 receptor. Shalaby et al., J. Exp. Med. 175(1):217 (1992). Bispecific antibodies have been tested in several early phase clinical trials with encouraging results. In one trial, 12 patients with lung, ovarian or breast cancer were treated with infusions of activated T-lymphocytes targeted with an anti-CD3/anti-tumor (MOC31) bispecific antibody. deLeij et al. Bispecific Antibodies and Targeted Cellular Cytotoxicity, Romet-Lemonne, Fanger and Segal Eds., Lienhart (1991) p. 249. The targeted cells induced considerable local lysis of tumor cells, a mild inflammatory reaction, but no toxic side effects or anti-mouse antibody responses. In a very preliminary trial of an anti-CD3/anti-CD19 bispecific antibody in a patient with B-cell malignancy, significant reduction in peripheral tumor cell counts was also achieved. Clark et al. Bispecific Antibodies and Targeted Cellular Cytotoxicity, Romet-Lemonne, Fanger and Segal Eds., Lienhart (1991) p. 243. See also Kroesen et al., Cancer Immunol. Immunother. 37:400-407 (1993), Kroesen et al., Br. J. Cancer 70:652-661 (1994) and Weiner et al., J. Immunol. 152:2385 (1994) concerning therapeutic applications for BsAbs.

Bispecific antibodies may also be used as fibrinolytic agents or vaccine adjuvants. Furthermore, these antibodies may be used in the treatment of infectious diseases (e.g. for targeting of effector cells to virally infected cells such as HIV or influenza virus or protozoa such as

*Toxoplasma gondii*), used to deliver immunotoxins to tumor cells, or target immune complexes to cell surface receptors (see Fanger et al., *supra*).

Use of BsAbs has been effectively stymied by the difficulty of obtaining BsAbs in sufficient quantity and purity. Traditionally,  
5 bispecific antibodies were made using hybrid-hybridoma technology (Millstein and Cuello, *Nature* 305:537-539 [1983]). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure (see Fig. 1 herein).  
10 The purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low. Accordingly, techniques for the production of greater yields of BsAb have been developed. These are depicted in Figs. 2A-2E herein. As shown in Fig. 2A, bispecific antibodies can be prepared using chemical linkage. To  
15 achieve chemical coupling of antibody fragments, Brennan et al., *Science* 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab'), fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation.  
20 The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the BsAb. The BsAbs produced can be used as agents for the selective immobilization of  
25 enzymes.

Recent progress has facilitated the direct recovery of Fab'-SH fragments from *E. coli*, which can be chemically coupled to form bispecific antibodies (see Fig. 2B). Shalaby et al., *J. Exp. Med.* 175:217-225 (1992) describe the production of a fully humanized BsAb F(ab'), molecule having  
30 one arm which binds p185<sup>HER2</sup> and another arm which binds CD3. Each Fab' fragment was separately secreted from *E. coli*, and subjected to directed chemical coupling *in vitro* to form the BsAb. The BsAb thus formed was able to bind to cells overexpressing the HER2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes  
35 against human breast tumor targets. See also Rodrigues et al., *Int. J. Cancers* (Suppl.) 7:45-50 (1992).

Various techniques for making and isolating BsAb fragments directly from recombinant cell cultures have also been described. For example, bispecific F(ab'), heterodimers have been produced using leucine zippers  
40 (see Fig. 2C). Kostelny et al., *J. Immunol.* 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of anti-CD3 and anti-interleukin-2 receptor (IL-2R) antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then reoxidized to form the antibody heterodimers. The BsAbs were found to be highly effective in recruiting cytotoxic T cells to lyse HuT-102 cells *in vitro*. The advent of the  
45

"diabody" technology described by Hollinger et al., PNAS (USA) 90:6444-6448 (1993) has provided an alternative mechanism for making BsAb fragments. The fragments comprise a heavy chain variable domain ( $V_h$ ) connected to a light chain variable domain ( $V_l$ ) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the  $V_h$  and  $V_l$  domains of one fragment are forced to pair with the complementary  $V_l$  and  $V_h$  domains of another fragment, thereby forming two antigen-binding sites (see Fig. 2D herein). Another strategy for making BsAb fragments by the use of single chain Fv (sFv) dimers has also been reported. See Gruber et al. J. Immunol. 152: 5368 (1994). These researchers designed an antibody which comprised the  $V_h$  and  $V_l$  domains of an antibody directed against the T cell receptor joined by a 25 amino acid residue linker to the  $V_h$  and  $V_l$  domains of an anti-fluorescein antibody. The refolded molecule (see Fig. 2E herein) bound to fluorescein and the T cell receptor and redirected the lysis of human tumor cells that had fluorescein covalently linked to their surface.

It is apparent that several techniques for making bispecific antibody fragments which can be recovered directly from recombinant cell culture have been reported. However, full length BsAbs may be preferable to BsAb fragments for many clinical applications because of their likely longer serum half-life and possible effector functions.

#### Immunoadhesins

Immunoadhesins (Ia's) are antibody-like molecules which combine the binding domain of a protein such as a cell-surface receptor or a ligand (an "adhesin") with the effector functions of an immunoglobulin constant domain. Immunoadhesins can possess many of the valuable chemical and biological properties of human antibodies. Since immunoadhesins can be constructed from a human protein sequence with a desired specificity linked to an appropriate human immunoglobulin hinge and constant domain (Fc) sequence, the binding specificity of interest can be achieved using entirely human components. Such immunoadhesins are minimally immunogenic to the patient, and are safe for chronic or repeated use.

Immunoadhesins reported in the literature include fusions of the T cell receptor (Gascoigne et al., Proc. Natl. Acad. Sci. USA 84:2936-2940 [1987]); CD4 (Capon et al., Nature 337:525-531 [1989]; Traunecker et al., Nature 339:68-70 [1989]; Zettmeissl et al., DNA Cell Biol. USA 9:347-353 [1990]; and Byrn et al., Nature 344:667-670 [1990]); L-selectin or homing receptor (Watson et al., J. Cell. Biol. 110:2221-2229 [1990]; and Watson et al., Nature 349:164-167 [1991]); CD44 (Aruffo et al., Cell 61:1303-1313 [1990]); CD28 and B7 (Linsley et al., J. Exp. Med. 173:721-730 [1991]); CTLA-4 (Lisley et al., J. Exp. Med. 174:561-569 [1991]); CD22 (Stamenkovic et al., Cell 66:1133-1144 [1991]); TNF receptor (Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 [1991]; Lesslauer et al., Eur. J. Immunol. 27:2883-2886 [1991]; and Peppel et al., J. Exp. Med. 174:1483-1489 [1991]); NP receptors (Bennett et al., J. Biol. Chem. 266:23060-23067

[1991]); interferon  $\gamma$  receptor (Kurschner et al., J. Biol. Chem. 267:9354-9360 [1992]); 4-1BB (Chalupny et al., PNAS [USA] 89:10360-10364 [1992]) and IgE receptor  $\alpha$  (Ridgway and Gorman, J. Cell. Biol. Vol. 115, Abstract No. 1448 [1991]).

5 Examples of immunoadhesins which have been described for therapeutic use include the CD4-IgG immunoadhesin for blocking the binding of HIV to cell-surface CD4. Data obtained from Phase I clinical trials in which CD4-IgG was administered to pregnant women just before delivery suggests that this immunoadhesin may be useful in the prevention of maternal-fetal transfer of HIV. Ashkenazi et al., Intern. Rev. Immunol. 10:219-227 (1993). An immunoadhesin which binds tumor necrosis factor (TNF) has also been developed. TNF is a proinflammatory cytokine which has been shown to be a major mediator of septic shock. Based on a mouse model of septic shock, a TNF receptor immunoadhesin has shown promise as a candidate for 10 clinical use in treating septic shock (Ashkenazi et al., *supra*). Immunoadhesins also have non-therapeutic uses. For example, the L-selectin receptor immunoadhesin was used as an reagent for histochemical staining of peripheral lymph node high endothelial venules (HEV). This reagent was 15 also used to isolate and characterize the L-selectin ligand (Ashkenazi et al., *supra*).  
20

If the two arms of the immunoadhesin structure have different specificities, the immunoadhesin is called a "bispecific immunoadhesin" by analogy to bispecific antibodies. Dietsch et al., J. Immunol. Methods 162:123 (1993) describe such a bispecific immunoadhesin combining the 25 extracellular domains of the adhesion molecules, E-selectin and P-selectin. Binding studies indicated that the bispecific immunoglobulin fusion protein so formed had an enhanced ability to bind to a myeloid cell line compared to the monospecific immunoadhesins from which it was derived.

#### Antibody-Immunoadhesin chimeras

30 Antibody-immunoadhesin (Ab/Ia) chimeras have also been described in the literature. These molecules combine the binding region of an immunoadhesin with the binding domain of an antibody.

Berg et al., PNAS (USA) 88:4723-4727 (1991) made a bispecific antibody-immunoadhesin chimera which was derived from murine CD4-IgG. These 35 workers constructed a tetrameric molecule having two arms. One arm was composed of CD4 fused with an antibody heavy-chain constant domain along with a CD4 fusion with an antibody light-chain constant domain. The other arm was composed of a complete heavy-chain of an anti-CD3 antibody along with a complete light-chain of the same antibody. By virtue of the CD4-IgG 40 arm, this bispecific molecule binds to CD3 on the surface of cytotoxic T cells. The juxtaposition of the cytotoxic cells and HIV-infected cells results in specific killing of the latter cells.

While Berg et al. describe a bispecific molecule that was tetrameric in structure, it is possible to produce a trimeric hybrid molecule that 45 contains only one CD4-IgG fusion. See Chamow et al., J. Immunol. 153:4268

(1994). The first arm of this construct is formed by a humanized anti-CD3  $\kappa$  light chain and a humanized anti-CD3  $\gamma$  heavy chain. The second arm is a CD4-IgG immunoadhesin which combines part of the extracellular domain of CD4 responsible for gp120 binding with the Fc domain of IgG. The resultant 5 Ab/Ia chimera mediated killing of HIV-infected cells using either pure cytotoxic T cell preparations or whole peripheral blood lymphocyte (PBL) fractions that additionally included Fc receptor-bearing large granular lymphocyte effector cells.

In the manufacture of the above-mentioned heteromultimers, it is 10 desirable to increase the yields of the desired heteromultimer over the homomultimer(s). The invention described herein provides a means for achieving this.

#### SUMMARY OF THE INVENTION

This application describes a "protuberance-into-cavity" strategy 15 which serves to engineer an interface between a first and second polypeptide for hetero-oligomerization. See Fig. 4 for a schematic illustration of the strategy employed. The preferred interface comprises at least a part of the C<sub>h</sub>3 domain of an antibody constant domain. "Protuberances" are constructed by replacing small amino acid side chains 20 from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the protuberances are optionally created on the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). Where a suitably positioned and 25 dimensioned protuberance or cavity exists at the interface of either the first or second polypeptide, it is only necessary to engineer a corresponding cavity or protuberance, respectively, at the adjacent interface.

Accordingly, the invention can be said to relate to a method of 30 preparing a heteromultimer comprising a first polypeptide and a second polypeptide which meet at an interface, wherein the first polypeptide has a protuberance at the interface thereof which is positionable in a cavity at the interface of the second polypeptide. In one aspect, the method involves: (a) culturing a host cell comprising nucleic acid encoding the 35 first polypeptide and second polypeptide, wherein the nucleic acid encoding the first polypeptide has been altered from the original nucleic acid to encode the protuberance or the nucleic acid encoding the second polypeptide has been altered from the original nucleic acid to encode the cavity, or both, such that the nucleic acid is expressed; and (b) recovering the 40 heteromultimer from the host cell culture.

Normally, the nucleic acid encoding both the first polypeptide and the second polypeptide are altered to encode the protuberance and cavity, respectively. Preferably the first and second polypeptides each comprise an antibody constant domain such as the C<sub>h</sub>3 domain of a human IgG<sub>1</sub>.

The invention also provides a heteromultimer (such as a bispecific antibody, bispecific immun adhesin or antibody/immunoadhesin chimera) comprising a first polypeptide and a second polypeptide which meet at an interface. The interface of the first polypeptide comprises a protuberance 5 which is positionable in a cavity in the interface of the second polypeptide, and the protuberance or cavity, or both, have been introduced into the interface of the first and second polypeptides respectively. The heteromultimer may be provided in the form of a composition further comprising a pharmaceutically acceptable carrier.

10 The invention also relates to a host cell comprising nucleic acid encoding the heteromultimer of the preceding paragraph wherein the nucleic acid encoding the first polypeptide and second polypeptide is present in a single vector or in separate vectors. The host cell can be used in a method of making a heteromultimer which involves culturing the host cell 15 so that the nucleic acid is expressed and recovering the heteromultimer from the cell culture.

In yet a further aspect, the invention provides a method of preparing a heteromultimer comprising:

- (a) altering a first nucleic acid encoding a first polypeptide so 20 that an amino acid residue in the interface of the first polypeptide is replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance on the first polypeptide;
- (b) altering a second nucleic acid encoding a second polypeptide so that an amino acid residue in the interface of the second polypeptide 25 is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity in the second polypeptide, wherein the protuberance is positionable in the cavity;
- (c) introducing into a host cell the first and second nucleic acids and culturing the host cell so that expression of the first and second 30 nucleic acid occurs; and
- (d) recovering the heteromultimer formed from the cell culture.

The invention provides a mechanism for increasing the yields of the heteromultimer over other unwanted end-products such as homomultimers. Preferably, the yields of the heteromultimer recovered from recombinant 35 cell culture are at least greater than 80% and preferably greater than 90% compared to the by-product homomultimer(s).

#### Brief Description of the Drawings

Fig. 1 depicts the various antibody molecules which may be generated when the traditional hybrid-hybridoma technique of Millstein and Cuello, 40 supra, is used for making full length BsAbs.

Figs. 2A-2E illustrate the various techniques of the background art for manufacturing BsAb fragments, reviewed in the background section above.

Figs. 3A-3C depict an exemplary strategy for making an immunoadhesin dimer (Fig. 3C) comprising the binding domain of a receptor (Fig. 3A) and 45 the constant domain of an IgG<sub>1</sub> immunoglobulin (Fig. 3B).

Fig. 4 illustrates schematically the protuberance-into-cavity strategy of the instant application for generating heteromultimers.

Fig. 5 shows the interface residues of the C<sub>H</sub>3 domain of the immunoglobulins IgG (SEQ ID NOS: 1-3), IgA (SEQ ID NO: 4), IgD (SEQ ID NO: 5), IgE (SEQ ID NO: 6) and IgM (SEQ ID NO: 7). The C<sub>H</sub>3 domain of each of these immunoglobulins is made up of a "β-sandwich", which is comprised of two separate and parallel "β-sheets". One of the β-sheets provides the interface residues, the other is the "exterior β-sheet". The β-sheet forming the interface is formed from four "β-strands". The residues of each of the seven β-strands of the C<sub>H</sub>3 domain of the various immunoglobulins are identified by dashed overlining. The residues in the middle and edge β-strands of the interface are identified, as are those of the exterior β-sheet. Residue numbering is according to Fc crystal structure (Deisenhofer, Biochem. 20:2361 [1981]). The residues buried in the interior of the C<sub>H</sub>3 domain are identified with a "B", those which are partially buried in the interior of the C<sub>H</sub>3 domain are identified with a "b", those "contact" residues which are partially buried at the interface (i.e. 26%-10% exposed) are identified with an "i" and those which are buried at the interface (i.e. <6% exposed) are identified with an "I". The bold residues are optimal candidate original residues for replacement with import residues.

Fig. 6 identifies the interface residues of human (h) (SEQ ID NOS: 8-11 and 16) or murine (m) (SEQ ID NOS: 12-15) IgG subtypes (B=ASX and Z=GLX). The residues in β-strands at the edge and middle of the interface are bracketed and "contact" residues are indicated with arrows. Sequences obtained from Miller et al., J. Mol. Biol. 216:965 (1990) and Kabat et al., Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda, MD, ed. 5, (1991). It is apparent that the contact residues are highly conserved.

Fig. 7 shows the interface residues of the C<sub>H</sub>3 domain of human IgG<sub>1</sub>. Data derived from Miller et al., J. Mol. Biol. 216:965 (1990). "Contact" residues are shown and those residues mutated in the examples described herein are boxed.

Fig. 8 shows schematically the co-transfection assay for examining Fc heterodimerization described in the examples.

Fig. 9 depicts a C<sub>H</sub>3 dimer based upon a 2.9 Å structure of human IgG, Fc (Deisenhofer, Biochem. 20:2361 [1981]) highlighting T366Y and Y407T mutations on opposite sides of the interface together with residues Phe<sup>105</sup> and Thr<sup>114</sup> ("Kabat numbering" - Kabat et al., Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda, MD, ed. 5, [1991]).

Figs. 10A-10E depict a scanning densitometric analysis of SDS-PAGE of products from co-transfection of antibody (Ab) heavy (H) and light (L) chains with immunoadhesin (Ia). Fig. 10A shows wild-type; Fig. 10B shows mutant Ab Y407T, Ia T366Y; Fig. 10C shows mutant Ab T366Y, Ia Y407T; Fig. 10D shows mutant Ab F405A, Ia T394W; and Fig. 10E shows mutant Ab

T366Y:F405A, Ia T394W:Y407T. Data presented are the mean from at least 2 independent experiments. The densitometric signal response was found to be linear ( $R = 0.9993$ ) over the experimental range used (0.02-10 $\mu$ g) as judged by control experiment using a closely related humanized antibody,  
5 huMAb4D5-8 (Carter et al., Proc. Natl. Acad. Sci. USA 89:4285 [1992]).

### I. Definitions

In general, the following words or phrases have the indicated definitions when used in the description, examples, and claims:

A "heteromultimer" or "heteromultimeric polypeptide" is a molecule  
10 comprising at least a first polypeptide and a second polypeptide, wherein the second polypeptide differs in amino acid sequence from the first polypeptide by at least one amino acid residue. Preferably, the heteromultimer has binding specificity for at least two different ligands or binding sites. The heteromultimer can comprise a "heterodimer" formed  
15 by the first and second polypeptide or can form higher order tertiary structures where polypeptides in addition to the first and second polypeptide are present. Exemplary structures for the heteromultimer include heterodimers (e.g. the bispecific immunoadhesin described by Dietsch et al., *supra*), heterotrimers (e.g. the Ab/Ia chimera described by  
20 Chamow et al., *supra*), heterotetramers (e.g. a bispecific antibody) and further oligomeric structures.

As used herein, "polypeptide" refers generally to peptides and proteins having more than about ten amino acids. Preferably, mammalian polypeptides (polypeptides that were originally derived from a mammalian organism) are used, more preferably those which are directly secreted into the medium. Examples of bacterial polypeptides include, e.g., alkaline phosphatase and  $\beta$ -lactamase. Examples of mammalian polypeptides include molecules such as renin, a growth hormone, including human growth hormone; bovine growth hormone; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; alpha-1-antitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; clotting factors such as factor VIIIC, factor IX, tissue factor, and von Willebrands factor; anti-clotting factors such as Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or human urine or tissue-type plasminogen activator (t-PA); bombesin; thrombin; hemopoietic growth factor; tumor necrosis factor-alpha and -beta; enkephalinase; RANTES (regulated on activation normally T-cell expressed and secreted); human macrophage inflammatory protein (MIP-1-alpha); a serum albumin such as human serum albumin; Muellerian-inhibiting substance; relaxin A-chain; relaxin B-chain; prorelaxin; mouse gonadotropin-associated peptide; a microbial protein, such as beta-lactamase; DNase; inhibin; activin; vascular endothelial growth factor (VEGF); receptors for hormones or growth factors; integrin; protein A or D; rheumatoid factors; a neurotrophic factor such as bone-derived neurotrophic factor (BDNF), neurotrophin-3, -4,

-5, or -6 (NT-3, NT-4, NT-5, or NT-6), or a nerve growth factor such as NGF- $\beta$ ; platelet-derived growth factor (PDGF); fibroblast growth factor such as aFGF and bFGF; epidermal growth factor (EGF); transforming growth factor (TGF) such as TGF-alpha and TGF-beta, including TGF- $\beta$ 1, TGF- $\beta$ 2, TGF- $\beta$ 3, 5 TGF- $\beta$ 4, or TGF- $\beta$ 5; insulin-like growth factor-I and -II (IGF-I and IGF-II); des(1-3)-IGF-I (brain IGF-I), insulin-like growth factor binding proteins; CD proteins such as CD-3, CD-4, CD-8, and CD-19; erythropoietin; osteoinductive factors; immunotoxins; a bone morphogenetic protein (BMP); 10 an interferon such as interferon-alpha, -beta, and -gamma; colony stimulating factors (CSFs), e.g., M-CSF, GM-CSF, and G-CSF; interleukins (ILs), e.g., IL-1 to IL-10; superoxide dismutase; T-cell receptors; surface membrane proteins; decay accelerating factor; viral antigen such as, for example, a portion of the AIDS envelope; transport proteins; homing receptors; addressins; regulatory proteins; antibodies; and fragments of 15 any of the above-listed polypeptides.

The "first polypeptide" is any polypeptide which is to be associated with a second polypeptide. The first and second polypeptide meet at an "interface" (defined below). In addition to the interface, the first polypeptide may comprise one or more additional domains, such as "binding 20 domains" (e.g. an antibody variable domain, receptor binding domain, ligand binding domain or enzymatic domain) or antibody constant domains (or parts thereof) including C<sub>H</sub>2, C<sub>H</sub>1 and C<sub>L</sub> domains. Normally, the first polypeptide will comprise at least one domain which is derived from an antibody. This domain conveniently is a constant domain, such as the C<sub>H</sub>3 domain of an 25 antibody and can form the interface of the first polypeptide. Exemplary first polypeptides include antibody heavy chain polypeptides, chimeras combining an antibody constant domain with a binding domain of a heterologous polypeptide (i.e. an immunoadhesin, see definition below), receptor polypeptides (especially those which form dimers with another 30 receptor polypeptide, e.g., interleukin-8 receptor [IL-8R] and integrin heterodimers [e.g. LFA-1 or GPIIb/IIIa]), ligand polypeptides (e.g. nerve growth factor [NGF], neurotrophin-3 [NT-3], and brain-derived neurotrophic factor [BDNF] - see Arakawa et al. J. Biol. Chem. 269(45): 27833-27839 35 [1994] and Radziejewski et al. Biochem. 32(48): 1350 [1993]) and antibody variable domain polypeptides (e.g. diabodies). The preferred first polypeptide is selected from an antibody heavy chain and an immunoadhesin.

The "second polypeptide" is any polypeptide which is to be associated with the first polypeptide via an "interface". In addition to the interface, the second polypeptide may comprise additional domains such as 40 a "binding domain" (e.g. an antibody variable domain, receptor binding domain, ligand binding domain or enzymatic domain), or antibody constant domains (or parts thereof) including C<sub>H</sub>2, C<sub>H</sub>1 and C<sub>L</sub> domains. Normally, the second polypeptide will comprise at least one domain which is derived from an antibody. This domain conveniently is a constant region, such as the 45 C<sub>H</sub>3 domain of an antibody and can form the interface of the second polypeptide. Exemplary second polypeptides include antibody heavy chain

polypeptides, chimeras combining an antibody constant domain with a binding domain of a heterologous polypeptide (i.e. an immunoadhesin, see definition below), receptor polypeptides (especially those which form dimers with another receptor polypeptide, e.g., interleukin-8 receptor [IL-8R] and 5 integrin heterodimers [e.g. LFA-1 or GPIIb/IIIa]), ligand polypeptides (e.g. nerve growth factor [NGF], neurotrophin-3 [NT-3], and brain-derived neurotrophic factor [BDNF] - see Arakawa et al. J. Biol. Chem. 269(45): 12

10 27833-27839 [1994] and Radziejewski et al. Biochem. 32(48): 1350 [1993]) and antibody variable domain polypeptides (e.g. diabodies). The preferred second polypeptide is selected from an antibody heavy chain and an immunoadhesin.

A "binding domain" comprises any region of a polypeptide which is responsible for selectively binding to a molecule of interest (e.g. an antigen, ligand, receptor, substrate or inhibitor). Exemplary binding 15 domains include an antibody variable domain, receptor binding domain, ligand binding domain and an enzymatic domain.

The term "antibody" shall mean a polypeptide containing one or more domains capable of binding an epitope on an antigen of interest, where such domain(s) are derived from or homologous with the variable region of an 20 antibody. Examples of antibodies include full length antibodies, antibody fragments, single chain molecules, bispecific or bifunctional molecules, diabodies, and chimeric antibodies (e.g. humanized and Primatized<sup>TM</sup> antibodies). "Antibody fragments" include Fv, Fv', Fab, Fab', and F(ab'), fragments.

"Humanized" forms of non-human (e.g. rodent or primate) antibodies are specific chimeric immunoglobulins, immunoglobulin chains or fragments thereof which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary 30 determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, rabbit or primate having the desired specificity, affinity and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, the 35 humanized antibody may comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and optimize antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or 40 substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. The humanized antibody includes 45 a Primatized<sup>TM</sup> antibody wherein the antigen-binding region of the antibody

is derived from an antibody produced by immunizing macaque monkeys with the antigen of interest.

A "multispecific antibody" is a molecule having binding specificities for at least two different antigens. While such molecules normally will only bind two antigens (i.e. bispecific antibodies, BsAbs), antibodies with additional specificities such as trispecific antibodies are encompassed by this expression when used herein. Examples of BsAbs include those with one arm directed against a tumor cell antigen and the other arm directed against a cytotoxic trigger molecule such as anti-Fc $\gamma$ RI/anti-CD15, anti-p185<sup>MR2</sup>/Fc $\gamma$ RIII (CD16), anti-CD3/anti-malignant B-cell (1D10), anti-CD3/anti-p185<sup>MR2</sup>, anti-CD3/anti-p97, anti-CD3/anti-renal cell carcinoma, anti-CD3/anti-OVCAR-3, anti-CD3/L-D1 (anti-colon carcinoma), anti-CD3/anti-melanocyte stimulating hormone analog, anti-EGF receptor/anti-CD3, anti-CD3/anti-CAM1, anti-CD3/anti-CD19, anti-CD3/MoV18, anti-neural cell adhesion molecule (NCAM)/anti-CD3, anti-folate binding protein (FBP)/anti-CD3, anti-pan carcinoma associated antigen (AMOC-31)/anti-CD3; BsAbs with one arm which binds specifically to a tumor antigen and one arm which binds to a toxin such as anti-saporin/anti-Id-1, anti-CD22/anti-saporin, anti-CD7/anti-saporin, anti-CD38/anti-saporin, anti-CEA/anti-ricin A chain, anti-interferon- $\alpha$ (IFN- $\alpha$ )/anti-hybridoma idiotype, anti-CEA/anti-vinca alkaloid; BsAbs for converting enzyme activated prodrugs such as anti-CD30/anti-alkaline phosphatase (which catalyzes conversion of mitomycin phosphate prodrug to mitomycin alcohol); BsAbs which can be used as fibrinolytic agents such as anti-fibrin/anti-tissue plasminogen activator (tPA), anti-fibrin/anti-urokinase-typeplasminogen activator (uPA); BsAbs for targeting immune complexes to cell surface receptors such as anti-low density lipoprotein (LDL)/anti-Fc receptor (e.g. Fc $\gamma$ RI, Fc $\gamma$ RII or Fc $\gamma$ RIII); BsAbs for use in therapy of infectious diseases such as anti-CD3/anti-herpes simplex virus (HSV), anti-T-cell receptor:CD3 complex/anti-influenza, anti-Fc $\gamma$ R/anti-HIV; BsAbs for tumor detection in vitro or in vivo such as anti-CEA/anti-EOTUBE, anti-CEA/anti-DPTA, anti-p185<sup>MR2</sup>/anti-hapten; BsAbs as vaccine adjuvants (see Fanger et al., *supra*); and BsAbs as diagnostic tools such as anti-rabbit IgG/anti-ferritin, anti-horse radish peroxidase (HRP)/anti-hormone, anti-somatostatin/anti-substance P, anti-HRP/anti-FITC, anti-CEA/anti- $\beta$ -galactosidase (see Nolan et al., *supra*). Examples of trispecific antibodies include anti-CD3/anti-CD4/anti-CD37, anti-CD3/anti-CD5/anti-CD37and anti-CD3/anti-CD8/anti-CD37.

As used herein, the term "immunoadhesin" designates antibody-like molecules which combine the "binding domain" of a heterologous protein (an "adhesin", e.g. a receptor, ligand or enzyme) with the effector functions of immunoglobulin constant domains. Structurally, the immunoadhesins comprise a fusion of the adhesin amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site (antigen combining site) of an antibody (i.e. is "heterologous") and an immunoglobulin constant domain sequence. The immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any

immunoglobulin, such as IgG<sub>1</sub>, IgG<sub>2</sub>, IgG<sub>3</sub>, or IgG<sub>4</sub>, subtypes, IgA, IgE, IgD or IgM.

The term "ligand binding domain" as used herein refers to any native cell-surface receptor or any region or derivative thereof retaining at least a qualitative ligand binding ability, and preferably the biological activity of a corresponding native receptor. In a specific embodiment, the receptor is from a cell-surface polypeptide having an extracellular domain which is homologous to a member of the immunoglobulin supergene family. Other typical receptors, are not members of the immunoglobulin supergene family but are nonetheless specifically covered by this definition, are receptors for cytokines, and in particular receptors with tyrosine kinase activity (receptor tyrosine kinases), members of the hematopoietin and nerve growth factor receptor superfamilies, and cell adhesion molecules, e. g. (E-, L- and P-) selectins.

The term "receptor binding domain" is used to designate any native ligand for a receptor, including cell adhesion molecules, or any region or derivative of such native ligand retaining at least a qualitative receptor binding ability, and preferably the biological activity of a corresponding native ligand. This definition, among others, specifically includes binding sequences from ligands for the above-mentioned receptors.

As used herein the phrase "multispecific immunoadhesin" designates immunoadhesins (as hereinabove defined) having at least two binding specificities (i.e. combining two or more adhesin binding domains). Multispecific immunoadhesins can be assembled as heterodimers, heterotrimers or heterotetramers, essentially as disclosed in WO 89/02922 (published 6 April 1989), in EP 314,317 (published 3 May 1989), and in U.S. Patent No. 5,116,964 issued 2 May 1992. Preferred multispecific immunoadhesins are bispecific. Examples of bispecific immunoadhesins include CD4-IgG/TNFreceptor-IgG and CD4-IgG/L-selectin-IgG. The last mentioned molecule combines the lymph node binding function of the lymphocyte homing receptor (LHR, L-selectin), and the HIV binding function of CD4, and finds potential application in the prevention or treatment of HIV infection, related conditions, or as a diagnostic.

An "antibody-immunoadhesin chimera (Ab/Ia chimera)" comprises a molecule which combines at least one binding domain of an antibody (as herein defined) with at least one immunoadhesin (as defined in this application). Exemplary Ab/Ia chimeras are the bispecific CD4-IgG chimeras described by Berg et al., *supra* and Chamow et al., *supra*.

The "interface" comprises those "contact" amino acid residues (or other non-amino acid groups such as carbohydrate groups, NADH, biotin, FAD or haem group) in the first polypeptide which interact with one or more "contact" amino acid residues (or other non-amino acid groups) in the interface of the second polypeptide. The preferred interface is a domain of an immunoglobulin such as a variable domain or constant domain (or regions thereof), however the interface between the polypeptides forming a heteromultimeric receptor or the interface between two or more ligands

such as NGF, NT-3 and BDNF are included within the scope of this term. The preferred interface comprises the C<sub>H</sub>3 domain of an immunoglobulin which preferably is derived from an IgG antibody and most preferably an human IgG, antibody.

5 A "protuberance" refers to at least one amino acid side chain which projects from the interface of the first polypeptide and is therefore positionable in a compensatory cavity in the adjacent interface (i.e. the interface of the second polypeptide) so as to stabilize the heteromultimer, and thereby favor heteromultimer formation over homomultimer formation, for  
10 example. The protuberance may exist in the original interface or may be introduced synthetically (e.g. by altering nucleic acid encoding the interface). Normally, nucleic acid encoding the interface of the first polypeptide is altered to encode the protuberance. To achieve this, the nucleic acid encoding at least one "original" amino acid residue in the  
15 interface of the first polypeptide is replaced with nucleic acid encoding at least one "import" amino acid residue which has a larger side chain volume than the original amino acid residue. It will be appreciated that there can be more than one original and corresponding import residue. The upper limit for the number of original residues which are replaced is the  
20 total number of residues in the interface of the first polypeptide. The side chain volumes of the various amino residues are shown in the following table.

TABLE 1  
Properties of Amino Acid Residues

	Amino Acid	One-Letter Abbr.	MASS <sup>a</sup> (daltons)	VOLUME <sup>b</sup> (Å <sup>3</sup> )	Accessible Surface Area <sup>c</sup> (Å <sup>2</sup> )
25	Alanine (Ala)	A	71.08	88.6	115
	Arginine (Arg)	R	156.20	173.4	225
	Asparagine (Asn)	N	114.11	117.7	160
30	Aspartic acid (Asp)	D	115.09	111.1	150
	Cysteine (Cys)	C	103.14	108.5	135
	Glutamine (Gln)	Q	128.14	143.9	180
	Glutamic acid (Glu)	E	129.12	138.4	190
35	Glycine (Gly)	G	57.06	60.1	75
	Histidine (His)	H	137.15	153.2	195
	Isoleucine (Ile)	I	113.17	166.7	175
	Leucine (Leu)	L	113.17	166.7	170
	Lysine (Lys)	K	128.18	168.6	200
40	Methionine (Met)	M	131.21	162.9	185

Phenylalanine (Phe)	F	147.18	189.9	210
Proline (Pro)	P	97.12	122.7	145
Serine (Ser)	S	87.08	89.0	115
Threonine (Thr)	T	101.11	116.1	140
Tryptophan (Trp)	W	186.21	227.8	255
Tyrosine (Tyr)	Y	163.18	193.6	230
Valine (Val)	V	99.14	140.0	155

10           \* Molecular weight amino acid minus that of water. Values from Handbook of Chemistry and Physics, 43rd ed. Cleveland, Chemical Rubber Publishing Co., 1961.

15           \* Values from A.A. Zamyatnin, Prog. Biophys. Mol. Biol. 24:107-123, 1972.

20           \* Values from C. Chothia, J. Mol. Biol. 105:1-14, 1975. The accessible surface area is defined in Figures 6-20 of this reference.

The preferred import residues for the formation of a protuberance are generally naturally occurring amino acid residues and are preferably selected from arginine (R), phenylalanine (F), tyrosine (Y) and tryptophan (W). Most preferred are tryptophan and tyrosine. In the preferred embodiment, the original residue for the formation of the protuberance has a small side chain volume, such as alanine, asparagine, aspartic acid, glycine, serine, threonine or valine.

25           A "cavity" refers to at least one amino acid side chain which is recessed from the interface of the second polypeptide and therefore accommodates a corresponding protuberance on the adjacent interface of the first polypeptide. The cavity may exist in the original interface or may be introduced synthetically (e.g. by altering nucleic acid encoding the interface). Normally, nucleic acid encoding the interface of the second polypeptide is altered to encode the cavity. To achieve this, the nucleic acid encoding at least one "original" amino acid residue in the interface of the second polypeptide is replaced with DNA encoding at least one "import" amino acid residue which has a smaller side chain volume than the original amino acid residue. It will be appreciated that there can be more than one original and corresponding import residue. The upper limit for the number of original residues which are replaced is the total number of residues in the interface of the second polypeptide. The side chain volumes of the various amino residues are shown in Table 1 above. The preferred import residues for the formation of a cavity are usually naturally occurring amino acid residues and are preferably selected from alanine (A), serine (S), threonine (T) and valine (V). Most preferred are serine, alanine or threonine. In the preferred embodiment, the original

residue for the formation of the protuberance has a large side chain volume, such as tyrosine, arginine, phenylalanine or tryptophan.

A "original" amino acid residue is one which is replaced by an "import" residue which can have a smaller or larger side chain volume than the original residue. The import amino acid residue can be a naturally occurring or non-naturally occurring amino acid residue, but preferably is the former. "Naturally occurring" amino acid residues are those residues encoded by the genetic code and listed in Table 1 above. By "non-naturally occurring" amino acid residue is meant a residue which is not encoded by the genetic code, but which is able to covalently bind adjacent amino acid residue(s) in the polypeptide chain. Examples of non-naturally occurring amino acid residues are norleucine, ornithine, norvaline, homoserine and other amino acid residue analogues such as those described in Ellman et al., Meth. Enzym. 202:301-336 (1991), for example. To generate such non-naturally occurring amino acid residues, the procedures of Noren et al. Science 244: 182 (1989) and Ellman et al., *supra* can be used. Briefly, this involves chemically activating a suppressor tRNA with a non-naturally occurring amino acid residue followed by *in vitro* transcription and translation of the RNA. The method of the instant invention involves replacing at least one original amino acid residue, but more than one original residue can be replaced. Normally, no more than the total residues in the interface of the first or second polypeptide will comprise original amino acid residues which are replaced. The preferred original residues for replacement are "buried". By "buried" is meant that the residue is essentially inaccessible to solvent. The preferred import residue is not cysteine to prevent possible oxidation or mispairing of disulfide bonds.

The protuberance is "positionable" in the cavity which means that the spatial location of the protuberance and cavity on the interface of the first polypeptide and second polypeptide respectively and the sizes of the protuberance and cavity are such that the protuberance can be located in the cavity without significantly perturbing the normal association of the first and second polypeptides at the interface. Since protuberances such as Tyr, Phe and Trp do not typically extend perpendicularly from the axis of the interface and have preferred conformations, the alignment of a protuberance with a corresponding cavity relies on modeling the protuberance/cavity pair based upon a three-dimensional structure such as that obtained by X-ray crystallography or nuclear magnetic resonance (NMR). This can be achieved using widely accepted techniques in the art.

By "original nucleic acid" is meant the nucleic acid encoding a polypeptide of interest which can be "altered" (i.e. genetically engineered or mutated) to encode a protuberance or cavity. The original or starting nucleic acid may be a naturally occurring nucleic acid or may comprise a nucleic acid which has been subjected to prior alteration (e.g. a humanized antibody fragment). By "altering" the nucleic acid is meant that the original nucleic acid is mutated by inserting, deleting or replacing at least one codon encoding an amino acid residue of interest. Normally, a

codon encoding an original residue is replaced by a codon encoding an import residue. Techniques for genetically modifying a DNA in this manner have been reviewed in Mutagenesis: a Practical Approach, M.J. McPherson, Ed., (IRL Press, Oxford, UK. (1991), and include site-directed mutagenesis, 5 cassette mutagenesis and polymerase chain reaction (PCR) mutagenesis, for example.

The protuberance or cavity can be "introduced" into the interface of the first or second polypeptide by synthetic means, e.g. by recombinant techniques, *in vitro* peptide synthesis, those techniques for introducing 10 non-naturally occurring amino acid residues previously described, by enzymatic or chemical coupling of peptides or some combination of these techniques. According, the protuberance or cavity which is "introduced" is "non-naturally occurring" or "non-native", which means that it does not exist in nature or in the original polypeptide (e.g. a humanized 15 monoclonal antibody).

Preferably the import amino acid residue for forming the protuberance has a relatively small number of "rotamers" (e.g. about 3-6). A "rotomer" is an energetically favorable conformation of an amino acid side chain. The 20 number of rotomers of the various amino acid residues are reviewed in Ponders and Richards, J. Mol. Biol. 193: 775-791 (1987).

"Isolated" heteromultimer means heteromultimer which has been identified and separated and/or recovered from a component of its natural cell culture environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or 25 therapeutic uses for the heteromultimer, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the heteromultimer will be purified (1) to greater than 95% by weight of protein as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain.

The heteromultimers of the present invention are generally purified to substantial homogeneity. The phrases "substantially homogeneous", 35 "substantially homogeneous form" and "substantial homogeneity" are used to indicate that the product is substantially devoid of by-products originated from undesired polypeptide combinations (e.g. homomultimers). Expressed in terms of purity, substantial homogeneity means that the amount of by-products does not exceed 1%, and preferably is below 5%, more preferably 40 below 1%, most preferably below 0.5%, wherein the percentages are by weight.

The expression "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, 45 for example, include a promoter, optionally an operator sequence, a ribosome binding site, and possibly, other as yet poorly understood

sequences. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accord with conventional practice.

## II. Preparation of the Heteromultimer

### 1. Preparation of the Starting Materials

As a first step, the first and second polypeptide (and any additional polypeptides forming the heteromultimer) are selected. Normally, the nucleic acid encoding these polypeptides needs to be isolated so that it can be altered to encode the protuberance or cavity, or both, as herein defined. However, the mutations can be introduced using synthetic means, e.g. by using a peptide synthesizer. Also, in the case where the import residue is a non-naturally occurring residue, the method of Noren et al., supra is available for making polypeptides having such substitutions. Additionally, part of the heteromultimer is suitably made recombinantly in cell culture and other part(s) of the molecule are made by those techniques mentioned above.

Techniques for isolating antibodies and preparing immunoadhesins follow. However, it will be appreciated that the heteromultimer can be formed from, or incorporate, other polypeptides using techniques which are known in the art. For example, nucleic acid encoding a polypeptide of interest (e.g. a ligand, receptor or enzyme) can be isolated from a cDNA library prepared from tissue believed to possess the polypeptide mRNA and to express it at a detectable level. Libraries are screened with probes (such as antibodies or oligonucleotides of about 20-80 bases) designed to identify the gene of interest or the protein encoded by it. Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures as described in chapters 10-12 of Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989).

(i) Antibody preparation

Several techniques for the production of antibodies have been described which include the traditional hybridoma method for making monoclonal antibodies, recombinant techniques for making antibodies (including chimeric antibodies, e.g. humanized antibodies), antibody production in transgenic animals and the recently described phage display technology for preparing "fully human" antibodies. These techniques shall be described briefly below.

Polyclonal antibodies to the antigen of interest generally can be raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the antigen and an adjuvant. It may be useful to conjugate the antigen (or a fragment containing the target amino acid sequence) to a protein that is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride,  $\text{SOCl}_2$ , or  $\text{R}^1\text{N}-\text{C}-\text{NR}$ , where R and  $\text{R}^1$  are different alkyl groups. Animals are immunized against the immunogenic conjugates or derivatives by combining 1 mg of 1  $\mu\text{g}$  of conjugate (for rabbits or mice, respectively) with 3 volumes of Freud's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with 1/5 to 1/10 the original amount of conjugate in Freud's complete adjuvant by subcutaneous injection at multiple sites. 7 to 14 days later the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus. Preferably, the animal is boosted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking reagent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are used to enhance the immune response.

Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies using the hybridoma method first described by Kohler & Milstein, *Nature* 256:495 (1975) or may be made by recombinant DNA methods (Cabilly et al., U.S. Patent No. 4,816,567). In the hybridoma method, a mouse or other appropriate host animal, such as hamster, is immunized as hereinabove described to elicit lymphocytes that produce, or are capable of producing, antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized *in vitro*. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, *Monoclonal Antibodies: Principles and Practice*, pp.59-103 [Academic Press, 1986]). The hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine

guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells. Preferred myeloma cells are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. Among these, preferred myeloma cell lines are murine myeloma lines, such as those derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2 cells available from the American Type Culture Collection, Rockville, Maryland USA. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 [1984]; and Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp.51-63, Marcel Dekker, Inc., New York, 1987). See, also, Boerner et al., J. Immunol., 147(1):86-95 (1991) and WO 91/17769, published Nov 28, 1991, for techniques for the production of human monoclonal antibodies. Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen of interest. Preferably, the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).

The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson & Pollard, Anal. Biochem. 107:220 (1980). After hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard methods. Goding, Monoclonal Antibodies: Principles and Practice, pp.59-104 (Academic Press, 1986). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium or RPMI-1640 medium. In addition, the hybridoma cells may be grown *in vivo* as ascites tumors in an animal. The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

Alternatively, it is now possible to produce transgenic animals (e.g. mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, it has been described that the homozygous deletion of the antibody heavy chain joining region ( $J_h$ ) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. See, e.g., Jakobovits et al., Proc.

Natl. Acad. Sci. USA 90:2551-255 (1993) and Jakobovits et al., Nature 362:255-258 (1993).

In a further embodiment, antibodies or antibody fragments can be isolated from antibody phage libraries generated using the techniques described in McCafferty et al., Nature, 348:552-554 (1990), using the antigen of interest to select for a suitable antibody or antibody fragment. Clackson et al., Nature, 352:624-628 (1991) and Marks et al., J. Mol. Biol., 222:581-597 (1991) describe the isolation of murine and human antibodies, respectively, using phage libraries. Subsequent publications describe the production of high affinity (nM range) human antibodies by chain shuffling (Mark et al., Bio/Technol. 10:779-783 [1992]), as well as combinatorial infection and in vivo recombination as a strategy for constructing very large phage libraries (Waterhouse et al., Nuc. Acids Res., 21:2265-2266 [1993]). Thus, these techniques are viable alternatives to traditional monoclonal antibody hybridoma techniques for isolation of "monoclonal" antibodies (especially human antibodies) which are encompassed by the present invention.

DNA encoding the antibodies of the invention is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences, Morrison et al., Proc. Nat. Acad. Sci. 81:6851 (1984). In that manner, "chimeric" antibodies are prepared that have the binding specificity of an anti-antigen monoclonal antibody herein.

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones et al., Nature 321:522-525 [1986]; Riechmann et al., Nature 332:323-327 [1988]; Verhoeyen et al., Science 239:1534-1536 [1988]), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (Cabilly, *supra*), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues, and possibly some FR residues, are substituted by residues from analogous sites in rodent antibodies. It is important

that antibodies be humanized with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual 5 humanized products using three dimensional models of the parental and humanized sequences. Three dimensional immunoglobulin models are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these 10 displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the consensus and import sequence so that the desired antibody 15 characteristic, such as increased affinity for the target antigen(s), is achieved. For further details see WO 92/22653, published Dec 23, 1992.

(ii) Immunoadhesin preparation

Immunoglobulins (Ig) and certain variants thereof are known and many have been prepared in recombinant cell culture. For example, see U.S. 20 Patent No. 4,745,055; EP 256,654; Faulkner et al., Nature 298:286 (1982); EP 120,694; EP 125,023; Morrison, J. Immun. 123:793 (1979); Köhler et al., Proc. Natl. Acad. Sci. USA 77:2197 (1980); Raso et al., Cancer Res. 41:2073 (1981); Morrison et al., Ann. Rev. Immunol. 2:239 (1984); Morrison, Science 229:1202 (1985); Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851 (1984); EP 255,694; EP 266,663; and WO 88/03559. Reassorted immunoglobulin 25 chains also are known. See, for example, U.S. Patent No. 4,444,878; WO 88/03565; and EP 68,763 and references cited therein.

Chimeras constructed from an adhesin binding domain sequence linked to an appropriate immunoglobulin constant domain sequence (immunoadhesins) 30 are known in the art. Immunoadhesins reported in the literature include fusions of the T cell receptor (Gascoigne et al., Proc. Natl. Acad. Sci. USA 84:2936-2940 [1987]); CD4 (Capon et al., Nature 337:525-531 [1989]; Traunecker et al., Nature 339:68-70 [1989]; Zettmeissl et al., DNA Cell Biol. USA 9:347-353 [1990]; and Byrn et al., Nature 344:667-670 [1990]); L-selectin (homing receptor) (Watson et al., J. Cell. Biol. 110:2221-2229 35 [1990]; and Watson et al., Nature 349:164-167 [1991]); CD44 (Aruffo et al., Cell 61:1303-1313 [1990]); CD28 and B7 (Linsley et al., J. Exp. Med. 173:721-730 [1991]); CTLA-4 (Lisley et al., J. Exp. Med. 174:561-569 [1991]); CD22 (Stamenkovic et al., Cell 66:1133-1144 [1991]); TNF receptor 40 (Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 [1991]; Lesslauer et al., Eur. J. Immunol. 27:2883-2886 [1991]; and Peppel et al., J. Exp. Med. 174:1483-1489 [1991]); and IgE receptor  $\alpha$  (Ridgway and Gorman, J. Cell. Biol., Vol. 115, Abstract No. 1448 [1991]).

The simplest and most straightforward immunoadhesin design combines 45 the binding domain(s) of the adhesin (e.g. the extracellular domain (ECD) of a receptor) with the hinge and Fc regions of an immunoglobulin heavy

chain (see Fig. 3). Ordinarily, when preparing the immunoadhesins of the present invention, nucleic acid encoding the binding domain of the adhesin will be fused C-terminally to nucleic acid encoding the N-terminus of an immunoglobulin constant domain sequence, however N-terminal fusions are 5 also possible.

Typically, in such fusions the encoded chimeric polypeptide will retain at least functionally active hinge, C<sub>H</sub>2 and C<sub>H</sub>3 domains of the constant region of an immunoglobulin heavy chain. Fusions are also made to the C-terminus of the Fc portion of a constant domain, or immediately 10 N-terminal to the C<sub>H</sub>1 of the heavy chain or the corresponding region of the light chain. The precise site at which the fusion is made is not critical; particular sites are well known and may be selected in order to optimize the biological activity, secretion, or binding characteristics of the Ia.

In a preferred embodiment, the adhesin sequence is fused to the N-terminus of the Fc domain of immunoglobulin G<sub>1</sub> (IgG<sub>1</sub>). It is possible to fuse the entire heavy chain constant region to the adhesin sequence. However, more preferably, a sequence beginning in the hinge region just upstream of the papain cleavage site which defines IgG Fc chemically (i.e. residue 216, taking the first residue of heavy chain constant region to be 15 114), or analogous sites of other immunoglobulins is used in the fusion. In a particularly preferred embodiment, the adhesin amino acid sequence is fused to (a) the hinge region and C<sub>H</sub>2 and C<sub>H</sub>3 or (b) the C<sub>H</sub>1, hinge, C<sub>H</sub>2 and C<sub>H</sub>3 domains, of an IgG<sub>1</sub>, IgG<sub>2</sub>, or IgG<sub>3</sub> heavy chain. The precise site at 20 25 which the fusion is made is not critical, and the optimal site can be determined by routine experimentation.

For bispecific immunoadhesins, the immunoadhesins are assembled as multimers, and particularly as heterodimers or heterotetramers. Generally, these assembled immunoglobulins will have known unit structures. A basic four chain structural unit is the form in which IgG, IgD, and IgE exist. 30 A four chain unit is repeated in the higher molecular weight immunoglobulins; IgM generally exists as a pentamer of four basic units held together by disulfide bonds. IgA globulin, and occasionally IgG globulin, may also exist in multimeric form in serum. In the case of multimer, each of the four units may be the same or different.

35 Various exemplary assembled immunoadhesins within the scope herein are schematically diagrammed below:

- (a) AC<sub>L</sub>-AC<sub>L</sub>;
- (b) AC<sub>H</sub>-[AC<sub>H</sub>, AC<sub>L</sub>-AC<sub>H</sub>, AC<sub>L</sub>-V<sub>H</sub>C<sub>H</sub>, or V<sub>L</sub>C<sub>L</sub>-AC<sub>H</sub>];
- (c) AC<sub>L</sub>-AC<sub>H</sub>-[AC<sub>L</sub>-AC<sub>H</sub>, AC<sub>L</sub>-V<sub>H</sub>C<sub>H</sub>, V<sub>L</sub>C<sub>L</sub>-AC<sub>H</sub>, or V<sub>L</sub>C<sub>L</sub>-V<sub>H</sub>C<sub>H</sub>];
- (d) AC<sub>L</sub>-V<sub>H</sub>C<sub>H</sub>-[AC<sub>H</sub>, or AC<sub>L</sub>-V<sub>H</sub>C<sub>H</sub>, or V<sub>L</sub>C<sub>L</sub>-AC<sub>H</sub>];
- (e) V<sub>L</sub>C<sub>L</sub>-AC<sub>H</sub>-[AC<sub>L</sub>-V<sub>H</sub>C<sub>H</sub>, or V<sub>L</sub>C<sub>L</sub>-AC<sub>H</sub>]; and
- (f) [A-Y]<sub>n</sub>-[V<sub>L</sub>C<sub>L</sub>-V<sub>H</sub>C<sub>H</sub>],;

wherein each A represents identical or different adhesin amino acid sequences;

45 V<sub>L</sub> is an immunoglobulin light chain variable domain;  
V<sub>H</sub> is an immunoglobulin heavy chain variable domain;

$C_L$  is an immunoglobulin light chain constant domain;  
 $C_H$  is an immunoglobulin heavy chain constant domain;  
n is an integer greater than 1;  
 $\gamma$  designates the residue of a covalent cross-linking agent.

5 In the interests of brevity, the foregoing structures only show key features; they do not indicate joining (J) or other domains of the immunoglobulins, nor are disulfide bonds shown. However, where such domains are required for binding activity, they shall be constructed to be present in the ordinary locations which they occupy in the immunoglobulin  
10 molecules.

Alternatively, the adhesin sequences can be inserted between immunoglobulin heavy chain and light chain sequences, such that an immunoglobulin comprising a chimeric heavy chain is obtained. In this embodiment, the adhesin sequences are fused to the 3' end of an  
15 immunoglobulin heavy chain in each arm of an immunoglobulin, either between the hinge and the  $C_H2$  domain, or between the  $C_H2$  and  $C_H3$  domains. Similar constructs have been reported by Hoogenboom, et al., Mol. Immunol. 28:1027-1037 (1991).

Although the presence of an immunoglobulin light chain is not required in the immunoadhesins of the present invention, an immunoglobulin light chain might be present either covalently associated to an adhesin-immunoglobulin heavy chain fusion polypeptide, or directly fused to the adhesin. In the former case, DNA encoding an immunoglobulin light chain is typically coexpressed with the DNA encoding the adhesin-immunoglobulin heavy chain fusion protein. Upon secretion, the hybrid heavy chain and the light chain will be covalently associated to provide an immunoglobulin-like structure comprising two disulfide-linked immunoglobulin heavy chain-light chain pairs. Methods suitable for the preparation of such structures are, for example, disclosed in U.S. Patent No. 4,816,567, issued 28 March 1989.

30 In a preferred embodiment, the immunoglobulin sequences used in the construction of the immunoadhesins of the present invention are from an IgG immunoglobulin heavy chain constant domain. For human immunoadhesins, the use of human IgG<sub>1</sub> and IgG<sub>3</sub> immunoglobulin sequences is preferred. A major advantage of using IgG<sub>1</sub> is that IgG<sub>1</sub> immunoadhesins can be purified  
35 efficiently on immobilized protein A. In contrast, purification of IgG<sub>3</sub> requires protein G, a significantly less versatile medium. However, other structural and functional properties of immunoglobulins should be considered when choosing the Ig fusion partner for a particular immunoadhesin construction. For example, the IgG<sub>1</sub> hinge is longer and more flexible, so it can accommodate larger "adhesin" domains that may not fold or function properly when fused to IgG<sub>1</sub>. Another consideration may be valency; IgG immunoadhesins are bivalent homodimers, whereas Ig subtypes like IgA and IgM may give rise to dimeric or pentameric structures, respectively, of the basic Ig homodimer unit. For immunoadhesins designed  
40 for in vivo application, the pharmacokinetic properties and the effector functions specified by the Fc region are important as well. Although IgG<sub>1</sub>,  
45

IgG<sub>1</sub> and IgG<sub>4</sub> all have *in vivo* half-lives of 21 days, their relative potencies at activating the complement system are different. IgG<sub>1</sub> does not activate complement, and IgG<sub>4</sub> is significantly weaker at complement activation than IgG<sub>1</sub>. More ver, unlike IgG<sub>1</sub>, IgG<sub>4</sub> does n't bind to Fc receptors on mononuclear cells or neutrophils. While IgG<sub>3</sub> is optimal for complement activation, its *in vivo* half-life is approximately one third of the other IgG isotypes. Another important consideration for immunoadhesins designed to be used as human therapeutics is the number of allotypic variants of the particular isotype. In general, IgG isotypes with fewer serologically-defined allotypes are preferred. For example, IgG<sub>1</sub> has only four serologically-defined allotypic sites, two of which (G1m and 2) are located in the Fc region; and one of these sites, G1m1, is non-immunogenic. In contrast, there are 12 serologically-defined allotypes in IgG<sub>3</sub>, all of which are in the Fc region; only three of these sites (G3m5, 11 and 21) have one allotype which is nonimmunogenic. Thus, the potential immunogenicity of a  $\gamma_3$  immunoadhesin is greater than that of a  $\gamma_1$  immunoadhesin.

Immunoadhesins are most conveniently constructed by fusing the cDNA sequence encoding the adhesin portion in-frame to an Ig cDNA sequence. However, fusion to genomic Ig fragments can also be used (see, e.g. Gascoigne et al., *supra*; Aruffo et al., *Cell* 61:1303-1313 [1990]; and Stamenkovic et al., *Cell* 66:1133-1144 [1991]). The latter type of fusion requires the presence of Ig regulatory sequences for expression. cDNAs encoding IgG heavy-chain constant regions can be isolated based on published sequences from cDNA libraries derived from spleen or peripheral blood lymphocytes, by hybridization or by polymerase chain reaction (PCR) techniques. The cDNAs encoding the "adhesin" and the Ig parts of the immunoadhesin are inserted in tandem into a plasmid vector that directs efficient expression in the chosen host cells.

30 2. Generating a Protuberance and/or Cavity

As a first step to selecting original residues for forming the protuberance and/or cavity, the three-dimensional structure of the heteromultimer is obtained using techniques which are well known in the art such as X-ray crystallography or NMR. Based on the three-dimensional structure, those skilled in the art will be able to identify the interface residues.

The preferred interface is the C<sub>H</sub>3 domain of an immunoglobulin constant domain. The interface residues of the C<sub>H</sub>3 domains of IgG, IgA, IgD, IgE and IgM are identified in Fig. 5, including those which are optimal for replacing with import residues. The interface residues of various IgG subtypes are illustrated in Fig. 6. "Buried" residues are also identified. The basis for engineering the C<sub>H</sub>3 interface is that X-ray crystallography has demonstrated that the intermolecular association between human IgG<sub>1</sub> heavy chains in the Fc region includes extensive protein/protein interaction between C<sub>H</sub>3 domains whereas the glycosylated C<sub>H</sub>2

domains interact via their carbohydrate (Deisenhofer, Biochem. 20:2361 [1981]). In addition there are two inter-heavy chain disulfide bonds which are efficiently formed during antibody expression in mammalian cells unless the heavy chain is truncated to remove C<sub>H</sub>2 and C<sub>H</sub>3 domains (King et al., 5 Biochem. J. 281:317 [1992]). Thus, heavy chain assembly appears to promote disulfide bond formation rather than vice versa. Taken together these structural and functional data led to the hypothesis that antibody heavy chain association is directed by the C<sub>H</sub>3 domains. It was further speculated that the interface between C<sub>H</sub>3 domains might be engineered to promote 10 formation of heteromultimers of different heavy chains and hinder assembly of corresponding homomultimers. The experiments described herein demonstrated that it was possible to promote the formation of heteromultimers over homomultimers using this approach. Thus, it is possible to generate a polypeptide fusion comprising a polypeptide of 15 interest and the C<sub>H</sub>3 domain of an antibody to form a first or second polypeptide. The preferred C<sub>H</sub>3 domain is derived from an IgG antibody, such as an human IgG<sub>1</sub>. The interface residues of human IgG<sub>1</sub> are depicted in Fig. 7.

Those interface residues which can potentially constitute candidates 20 for forming the protuberance or cavity are identified. It is preferable to select "buried" residues to be replaced. To determine whether a residue is buried, the surface accessibility program of Lee et al. J. Mol. Biol. 55: 379-400 (1971) can be used to calculate the solvent accessibility (SA) 25 of residues in the interface. Then, the SA for the residues of each of the first and second polypeptide can be separately calculated after removal of the other polypeptide. The difference in SA of each residue between the monomer and dimer forms of the interface can then be calculated by: SA (dimer) - SA (monomer). This provides a list of residues which lose SA on formation of the dimer. The SA of each residue in the dimer is compared 30 to the theoretical SA of the same amino acid in the tripeptide Gly-X-Gly, where X = the amino acid of interest (Rose et al. Science 229: 834-838 [1985]). Residues which (a) lost SA in the dimer compared to the monomer and (b) had an SA less than 26% of that in their corresponding tripeptide 35 are considered as interface residues. Two categories may be delineated: those which have an SA < 10% compared to their corresponding tripeptide (i.e. "buried") and those which have 25% > SA > 10% compared to their corresponding tripeptide (i.e. "partially buried").

TABLE 2

Residue No'	SA Lost Monomer → Dimer		Δ Tripeptide	
	Polypeptide A	Polypeptide B	Polypeptide A	Polypeptide B
Q347	22.1	31.0	25.0	26.5
Y349	79.8	83.9	5.2	5.7

L351	67.4	77.7	3.9	2.0
S354	53.4	52.8	11.3	11.7
B357	43.7	45.3	0.4	1.3
S364	21.5	15.1	0.5	1.4
T366	29.3	25.8	0.0	0.1
L368	25.5	29.7	1.0	1.1
K370	55.8	62.3	11.5	11.0
T394	64.0	58.5	0.6	1.4
V397	50.3	49.5	13.2	11.0
D399	39.7	33.7	5.7	5.7
F405	53.7	52.1	0.0	0.0
Y407	89.1	90.3	0.0	0.0
K409	86.8	92.3	0.7	0.6
T411	4.3	7.5	12.7	9.8

15 residue numbering as in IgG crystal structure (Deisenhofer, Biochemistry 20:2361-2370 [1981]).

The effect of replacing residues on the polypeptide chain structure can be studied using a molecular graphics modeling program such as the Insight™ program (Biosym Technologies). Using the program, those 20 buried residues in the interface of the first polypeptide which have a small side chain volume can be changed to residues having a larger side chain volume (i.e. a protuberance), for example. Then, the residues in the interface of the second polypeptide which are in proximity to the protuberance are examined to find a suitable residue for forming the 25 cavity. Normally, this residue will have a large side chain volume and is replaced with a residue having a smaller side chain volume. In certain embodiments, examination of the three-dimensional structure of the interface will reveal a suitably positioned and dimensioned protuberance on the interface of the first polypeptide or a cavity on the interface of 30 the second polypeptide. In these instances, it is only necessary to model a single mutant, i.e., with a synthetically introduced protuberance or cavity.

With respect to selecting potential original residues for replacement where the first and second polypeptide each comprise a C<sub>H</sub>3 domain, the 35 C<sub>H</sub>3/C<sub>H</sub>3 interface of human IgG<sub>1</sub> involves sixteen residues on each domain located on four anti-parallel β-strands which buries 1090 Å<sup>2</sup> from each surface (Deisenhofer, *supra*) and Miller, J. Mol. Biol. 216:965 [1990]). See Fig. 7 herein. Mutations are preferably targeted to residues located on the two central anti-parallel β-strands. The aim is to minimize the risk 40 that the protuberances which are created can be accommodated by protruding

into surrounding solvent rather than by compensatory cavities in the partner C<sub>H</sub>3 domain.

Once the preferred original/import residues are identified by molecular modeling, the amino acid replacements are introduced into the 5 polypeptide using techniques which are well known in the art. Normally the DNA encoding the polypeptide is genetically engineered using the techniques described in Mutagenesis: a Practical Approach, *supra*.

Oligonucleotide-mediated mutagenesis is a preferred method for preparing substitution variants of the DNA encoding the first or second 10 polypeptide. This technique is well known in the art as described by Adelman et al., DNA, 2:183 (1983). Briefly, first or second polypeptide DNA is altered by hybridizing an oligonucleotide encoding the desired mutation to a DNA template, where the template is the single-stranded form 15 of a plasmid or bacteriophage containing the unaltered or native DNA sequence of heteromultimer. After hybridization, a DNA polymerase is used to synthesize an entire second complementary strand of the template that will thus incorporate the oligonucleotide primer, and will code for the selected alteration in the heteromultimer DNA.

Cassette mutagenesis can be performed as described Wells et al. Gene 20 34:315 (1985) by replacing a region of the DNA of interest with a synthetic mutant fragment generated by annealing complimentary oligonucleotides. PCR mutagenesis is also suitable for making variants of the first or second 25 polypeptide DNA. While the following discussion refers to DNA, it is understood that the technique also finds application with RNA. The PCR technique generally refers to the following procedure (see Erlich, Science, 252:1643-1650 [1991], the chapter by R. Higuchi, p. 61-70).

This invention also encompasses, in addition to the protuberance or cavity mutations, amino acid sequence variants of the heteromultimer which can be prepared by introducing appropriate nucleotide changes into the 30 heteromultimer DNA, or by synthesis of the desired heteromultimer polypeptide. Such variants include, for example, deletions from, or insertions or substitutions of, residues within the amino acid sequences of the first and second polypeptides forming the heteromultimer. Any combination of deletion, insertion, and substitution is made to arrive at 35 the final construct, provided that the final construct possesses the desired antigen-binding characteristics. The amino acid changes also may alter post-translational processes of the heteromultimer, such as changing the number or position of glycosylation sites.

A useful method for identification of certain residues or regions of 40 the heteromultimer polypeptides that are preferred locations for mutagenesis is called "alanine scanning mutagenesis," as described by Cunningham and Wells, Science, 244:1081-1085 (1989). Here, a residue or group of target residues are identified (e.g. charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged 45 amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with the surrounding aqueous environment in

or outside the cell. Those domains demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at or for the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined.

Normally the mutations will involve conservative amino acid replacements in non-functional regions of the heteromultimer. Exemplary mutations are shown in the following table.

TABLE 3

	Original Residue	Exemplary Substitutions	Preferred Substitutions
10	Ala (A)	val; leu; ile	val
15	Arg (R)	lys; gln; asn	lys
20	Asn (N)	gln; his; lys; arg	gln
25	Asp (D)	glu	glu
30	Cys (C)	ser	ser
	Gln (Q)	asn	asn
	Glu (E)	asp	asp
	Gly (G)	pro; ala	ala
	His (H)	asn; gln; lys; arg	arg
	Ile (I)	leu; val; met; ala; phe; norleucine	leu
	Leu (L)	norleucine; ile; val; met; ala; phe	ile
	Lys (K)	arg; gln; asn	arg
	Met (M)	leu; phe; ile	leu
	Phe (F)	leu; val; ile; ala; tyr	leu
	Pro (P)	ala	ala
	Ser (S)	thr	thr
	Thr (T)	ser	ser
	Trp (W)	tyr; phe	tyr
	Tyr (Y)	trp; phe; thr; ser	phe
	Val (V)	ile; leu; met; phe; ala; norleucine	leu

Covalent modifications of the heteromultimer polypeptides are included within the scope of this invention. Covalent modifications of the heteromultimer can be introduced into the molecule by reacting targeted

amino acid residues of the heteromultimer or fragments thereof with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues. Another type of covalent modification of the heteromultimer polypeptide included within the scope 5 of this invention comprises altering the native glycosylation pattern of the polypeptide. By altering is meant deleting one or more carbohydrate moieties found in the original heteromultimer, and/or adding one or more glycosylation sites that are not present in the original heteromultimer. Addition of glycosylation sites to the heteromultimer polypeptide is 10 conveniently accomplished by altering the amino acid sequence such that it contains one or more N-linked glycosylation sites. The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the original heteromultimer sequence (for O-linked glycosylation sites). For ease, the heteromultimer amino acid sequence is 15 preferably altered through changes at the DNA level, particularly by mutating the DNA encoding the heteromultimer polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids. Another means of increasing the number of carbohydrate 20 moieties on the heteromultimer polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. These methods are described in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981). Removal of carbohydrate moieties 25 present on the heteromultimer may be accomplished chemically or enzymatically.

Another type of covalent modification of heteromultimer comprises linking the heteromultimer polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

Since it is often difficult to predict in advance the characteristics 30 of a variant heteromultimer, it will be appreciated that some screening of the recovered variant will be needed to select the optimal variant.

### 3. Expression of the Heteromultimer

Following mutation of the DNA as discussed in the preceding section, 35 the DNA encoding the molecule is expressed using recombinant techniques which are widely available in the art. Often, the expression system of choice will involve a mammalian cell expression vector and host so that the heteromultimer is appropriately glycosylated (e.g. in the case of heteromultimers comprising antibody domains which are glycosylated). 40 However, the molecules can also be produced in the prokaryotic expression systems elaborated below. Normally, the host cell will be transformed with DNA encoding both the first polypeptide and the second polypeptide and other polypeptide(s) required to form the heteromultimer, on a single vector or independent vectors. However, it is possible to express the

first polypeptide and second polypeptide in independent expression systems and couple the expressed polypeptides in vitro.

The nucleic acid (e.g., cDNA or genomic DNA) encoding the heteromultimer is inserted into a replicable vector for further cloning (amplification of the DNA) or for expression. Many vectors are available. The vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.

The polypeptides of the heteromultimer may be produced as fusion polypeptides with a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the DNA that is inserted into the vector. The heterologous signal sequence selected preferably is one that is recognized and processed (i.e., cleaved by a signal peptidase) by the host cell. For prokaryotic host cells, the signal sequence may be substituted by a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the native signal sequence may be substituted by, e.g., the yeast invertase leader, alpha factor leader (including *Saccharomyces* and *Kluyveromyces* α-factor leaders, the latter described in U.S. Pat. No. 5,010,182 issued 23 April 1991), or acid phosphatase leader, the *C. albicans* glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990. In mammalian cell expression the native signal sequence (e.g., the antibody or adhesin presequence that normally directs secretion of these molecules from human cells *in vivo*) is satisfactory, although other mammalian signal sequences may be suitable as well as viral secretory leaders, for example, the herpes simplex gD signal. The DNA for such precursor region is ligated in reading frame to DNA encoding the polypeptides forming the heteromultimer.

Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Generally, in cloning vectors this sequence is one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2μ plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells. Generally, the origin of replication component is not needed for mammalian expression vectors (the SV40 origin may typically be used only because it contains the early promoter).

Expression and cloning vectors should contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that

(a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli. One example of a selection scheme utilizes a drug to arrest growth of a host cell. Those cells that are successfully transformed with a heterologous gene produce a protein conferring drug resistance and thus survive the selection regimen. Examples of such dominant selection use the drugs neomycin (Southern et al., J. Molec. Appl. Genet. 1:327 [1982]), mycophenolic acid (Mulligan et al., Science 209:1422 [1980]) or hygromycin (Sugden et al., Mol. Cell. Biol. 5:410-413 [1985]). The three examples given above employ bacterial genes under eukaryotic control to convey resistance to the appropriate drug G418 or neomycin (geneticin), xgpt (mycophenolic acid), or hygromycin, respectively.

Another example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the heteromultimer nucleic acid, such as DHFR or thymidine kinase. The mammalian cell transformants are placed under selection pressure that only the transformants are uniquely adapted to survive by virtue of having taken up the marker. Selection pressure is imposed by culturing the transformants under conditions in which the concentration of selection agent in the medium is successively changed, thereby leading to amplification of both the selection gene and the DNA that encodes heteromultimer. Increased quantities of heteromultimer are synthesized from the amplified DNA. Other examples of amplifiable genes include metallothionein-I and -II, preferably primate metallothionein genes, adenosine deaminase, ornithine decarboxylase, etc.

For example, cells transformed with the DHFR selection gene are first identified by culturing all of the transformants in a culture medium that contains methotrexate (Mtx), a competitive antagonist of DHFR. An appropriate host cell when wild-type DHFR is employed is the Chinese hamster ovary (CHO) cell line deficient in DHFR activity, prepared and propagated as described by Urlaub and Chasin, Proc. Natl. Acad. Sci. USA 77:4216 (1980). The transformed cells are then exposed to increased levels of methotrexate. This leads to the synthesis of multiple copies of the DHFR gene, and, concomitantly, multiple copies of other DNA comprising the expression vectors, such as the DNA encoding the components of the heteromultimer. This amplification technique can be used with any otherwise suitable host, e.g., ATCC No. CCL61 CHO-K1, notwithstanding the presence of endogenous DHFR if, for example, a mutant DHFR gene that is highly resistant to Mtx is employed (EP 117,060).

Alternatively, host cells (particularly wild-type hosts that contain endogenous DHFR) transformed or co-transformed with DNA sequences encoding heteromultimer, wild-type DHFR protein, and another selectable marker such as aminoglycoside 3'-phosphotransf rase (APH) can be selected by cell growth in medium containing a selection agent for the selectable marker

such as an aminoglycosidic antibiotic, e.g., kanamycin, neomycin, or G418. See U.S. Patent No. 4,965,199.

A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7 (Stinchcomb et al., *Nature* 282:39 [1979]; 5 Kingsman et al., *Gene* 7:141 [1979]; or Tschemper et al., *Gene* 10:157 [1980]). The *trp1* gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 (Jones, *Genetics* 85:12 [1977]). The presence of the *trp1* lesion in the yeast host cell genome then provides an effective environment 10 for detecting transformation by growth in the absence of tryptophan. Similarly, Leu2-deficient yeast strains (ATCC 20,622 or 38,626) are complemented by known plasmids bearing the Leu2 gene.

In addition, vectors derived from the 1.6  $\mu$ m circular plasmid pKD1 can be used for transformation of *Kluyveromyces* yeasts. Bianchi et al., 15 *Curr. Genet.* 12:185 (1987). More recently, an expression system for large-scale production of recombinant calf chymosin was reported for *K. lactis*. Van den Berg, *Bio/Technology* 8:135 (1990). Stable multi-copy expression vectors for secretion of mature recombinant human serum albumin by industrial strains of *Kluyveromyces* have also been disclosed. Fleer et 20 al., *Bio/Technology* 9:968-975 (1991).

Expression and cloning vectors usually contain a promoter that is recognized by the host organism and is operably linked to the heteromultimer nucleic acid. A large number of promoters recognized by a variety of potential host cells are well known. These promoters are 25 operably linked to heteromultimer-encoding DNA by removing the promoter from the source DNA by restriction enzyme digestion and inserting the isolated promoter sequence into the vector.

Promoters suitable for use with prokaryotic hosts include the  $\beta$ -lactamase and lactose promoter systems (Chang et al., *Nature* 275:615 30 [1978]; and Goeddel et al., *Nature* 281:544 [1979]), alkaline phosphatase, a tryptophan (*trp*) promoter system (Goeddel, *Nucleic Acids Res.*, 8:4057 [1980] and EP 36,776) and hybrid promoters such as the tac promoter (deBoer et al., *Proc. Natl. Acad. Sci. USA* 80:21-25 [1983]). However, other known bacterial promoters are suitable. Their nucleotide sequences have been 35 published, thereby enabling a skilled worker operably to ligate them to DNA encoding the heteromultimer (Siebenlist et al., *Cell* 20:269 [1980]) using linkers or adaptors to supply any required restriction sites. Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding the heteromultimer.

40 Promoter sequences are known for eukaryotes. Virtually all eukaryotic genes have an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated. Another sequence found 70 to 80 bases upstream from the start of transcription of many genes is a CXCAAT region where X may be any nucleotide. At the 3' end 45 of most eukaryotic genes is an AATAAA sequence that may be the signal for

addition of the poly A tail to the 3' end of the coding sequence. All of these sequences are suitably inserted into eukaryotic expression vectors.

Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase (Hitzeman et al., J. Biol. Chem. 255:2073 [1980]) or other glycolytic enzymes (Hess et al., J. Adv. Enzyme Reg. 7:149 [1968]; and Holland, Biochemistry 17:4900 [1978]), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytchrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in Hitzeman et al., EP 73,657A. Yeast enhancers also are advantageously used with yeast promoters.

Heteromultimer transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and most preferably Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter or from heat-shock promoters.

The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment that also contains the SV40 viral origin of replication. Fiers et al., Nature 273:113 (1978); Mulligan and Berg, Science 209:1422-1427 (1980); Pavlakis et al., Proc. Natl. Acad. Sci. USA 78:7398-7402 (1981). The immediate early promoter of the human cytomegalovirus is conveniently obtained as a HindIII E restriction fragment. Greenaway et al., Gene 18:355-360 (1982). A system for expressing DNA in mammalian hosts using the bovine papilloma virus as a vector is disclosed in U.S. Patent No. 4,419,446. A modification of this system is described in U.S. Patent No. 4,601,978. See also Gray et al., Nature 295:503-508 (1982) on expressing cDNA encoding immune interferon in monkey cells; Reyes et al., Nature 297:598-601 (1982) on expression of human  $\beta$ -interferon cDNA in mouse cells under the control of a thymidine kinase promoter from herpes simplex virus; Canaani and Berg, Proc. Natl. Acad. Sci. USA 79:5166-5170 (1982) on expression of the human interferon  $\beta$ 1 gene in cultured mouse and rabbit cells; and Gorman et al., Proc. Natl. Acad. Sci. USA 79:6777-6781 (1982) on expression of bacterial CAT sequences in CV-1 monkey kidney cells, chicken embryo fibroblasts, Chinese hamster ovary cells, HeLa cells, and mouse NIH-3T3 cells using the Rous sarcoma virus long terminal repeat as a promoter.

Transcription of DNA encoding the heteromultimer by higher eukaryotes is often increased by inserting an enhancer sequence into the vector. Enhancers are relatively orientation and position independent, having been found 5' (Laimins et al., Proc. Natl. Acad. Sci. USA 78:993 [1981]) and 3' (Lusky et al., Mol. Cell Bio. 3:1108 [1983]) to the transcription unit, within an intron (Banerji et al., Cell 33:729 [1983]), as well as within the coding sequence itself (Osborne et al., Mol. Cell Bio. 4:1293 [1984]). Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin,  $\alpha$ -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. See also Yaniv, Nature 297:17-18 (1982) on enhancing elements for activation of eukaryotic promoters. The enhancer may be spliced into the vector at a position 5' or 3' to the heteromultimer-encoding sequence, but is preferably located at a site 5' from the promoter.

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding the heteromultimer.

Construction of suitable vectors containing one or more of the above listed components employs standard ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to generate the plasmids required.

For analysis to confirm correct sequences in plasmids constructed, the ligation mixtures are used to transform *E. coli* K12 strain 294 (ATCC 31,446) and successful transformants selected by ampicillin or tetracycline resistance where appropriate. Plasmids from the transformants are prepared, analyzed by restriction endonuclease digestion, and/or sequenced by the method of Messing et al., Nucleic Acids Res. 9:309 (1981) or by the method of Maxam et al., Methods in Enzymology 65:499 (1980).

Particularly useful in the practice of this invention are expression vectors that provide for the transient expression in mammalian cells of DNA encoding heteromultimer. In general, transient expression involves the use of an expression vector that is able to replicate efficiently in a host cell, such that the host cell accumulates many copies of the expression vector and, in turn, synthesizes high levels of a desired polypeptide encoded by the expression vector. Sambrook et al., *supra*, pp. 16.17 - 16.22. Transient expression systems, comprising a suitable expression vector and a host cell, allow for the convenient positive identification

of polypeptides encoded by cloned DNAs, as well as for the rapid screening of heteromultimers having desired binding specificities/affinities.

Other methods, vectors, and host cells suitable for adaptation to the synthesis of the heteromultimer in recombinant vertebrate cell culture are 5 described in Gething et al., Nature 293:620-625 (1981); Mantei et al., Nature 281:40-46 (1979); Levinson et al.; EP 117,060; and EP 117,058. A particularly useful plasmid for mammalian cell culture expression of the heteromultimer is pRK5 (EP 307,247) or pSVI6B (PCT pub. no. WO 91/08291 published 13 June 1991).

10 The choice of host cell line for the expression of heteromultimer depends mainly on the expression vector. Another consideration is the amount of protein that is required. Milligram quantities often can be produced by transient transfections. For example, the adenovirus E1A-transformed 293 human embryonic kidney cell line can be transfected 15 transiently with pRK5-based vectors by a modification of the calcium phosphate method to allow efficient heteromultimer expression. CDM8-based vectors can be used to transfect COS cells by the DEAE-dextran method (Aruffo et al., Cell 61:1303-1313 [1990]; and Zettmeissl et al., DNA Cell Biol. (US) 9:347-353 [1990]). If larger amounts of protein are desired, 20 the immunoadhesin can be expressed after stable transfection of a host cell line. For example, a pRK5-based vector can be introduced into Chinese hamster ovary (CHO) cells in the presence of an additional plasmid encoding dihydrofolate reductase (DHFR) and conferring resistance to G418. Clones resistant to G418 can be selected in culture. These clones are grown in the 25 presence of increasing levels of DHFR inhibitor methotrexate and clones are selected in which the number of gene copies encoding the DHFR and heteromultimer sequences is co-amplified. If the immunoadhesin contains a hydrophobic leader sequence at its N-terminus, it is likely to be processed and secreted by the transfected cells. The expression of 30 immunoadhesins with more complex structures may require uniquely suited host cells. For example, components such as light chain or J chain may be provided by certain myeloma or hybridoma host cells (Gascoigne et al., *supra*; and Martin et al., J. Virol. 67:3561-3568 [1993]).

Other suitable host cells for cloning or expressing the vectors 35 herein are prokaryote, yeast, or other higher eukaryote cells described above. Suitable prokaryotes for this purpose include eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as Escherichia, e.g., *E. coli*, *Enterobacter*, *Erwinia*, *Klebsiella*, *Proteus*, *Salmonella*, e.g., *Salmonella typhimurium*, *Serratia*, e.g., *Serratia marcescans*, and *Shigella*, as well as *Bacilli* such as *B. subtilis* and *B. licheniformis* (e.g., *B. licheniformis* 41P disclosed in DD 266,710 published 12 April 1989), *Pseudomonas* such as *P. aeruginosa*, and *Streptomyces*. One 40 preferred *E. coli* cloning host is *E. coli* 294 (ATCC 31,446), although other strains such as *E. coli* B, *E. coli* X1776 (ATCC 31,537), and *E. coli* W3110 (ATCC 27,325) are suitable. These examples are illustrative rather than 45 limiting. Strain W3110 is a particularly preferred host or parent host

because it is a common host strain for recombinant DNA product fermentations. Preferably, the host cell should secrete minimal amounts of proteolytic enzymes. For example, strain W3110 may be modified to effect a genetic mutation in the genes encoding proteins, with examples of such hosts including *E. coli* W3110 strain 27C7. The complete genotype of 5 27C7 is *tonAA* *ptr3* *phoAΔE15 Δ(argF-lac)169 ampTΔ degP41kanR*. Strain 27C7 was deposited on 30 October 1991 in the American Type Culture Collection 10 as ATCC No. 55,244. Alternatively, the strain of *E. coli* having mutant periplasmic protease disclosed in U.S. Patent No. 4,946,783 issued 7 August 1990 may be employed. Alternatively, methods of cloning, e.g., PCR or other nucleic acid polymerase reactions, are suitable.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for heteromultimer-encoding vectors. *Saccharomyces cerevisiae*, or common baker's yeast, is 15 the most commonly used among lower eukaryotic host microorganisms. However, a number of other genera, species, and strains are commonly available and useful herein, such as *Schizosaccharomyces pombe* (Beach and Nurse, *Nature* 290:140 [1981]; EP 139,383 published May 2, 1985); *Kluyveromyces* hosts (U.S. Patent No. 4,943,529; Fleer et al., *supra*) such 20 as, e.g., *K. lactis* [MW98-8C, CBS683, CBS4574; Louvencourt et al., *J. Bacteriol.*, 737 (1983)], *K. fragilis* (ATCC 12,424), *K. bulgaricus* (ATCC 16,045), *K. wickeramii* (ATCC 24,178), *K. waltii* (ATCC 56,500), *K. drosophilae* (ATCC 36,906; Van den Berg et al., *supra*), *K. thermotolerans*, and *K. marxianus*; *yarrowia* [EP 402,226]; *Pichia pastoris* 25 (EP 183,070; Sreekrishna et al., *J. Basic Microbiol.* 28:265-278 [1988]); *Candida*; *Trichoderma reesiae* [EP 244,234]; *Neurospora crassa* (Case et al., *Proc. Natl. Acad. Sci. USA* 76:5259-5263 [1979]); *Schwanniomyces* such as *Schwanniomyces occidentalis* (EP 394,538 published 31 October 1990); and 30 filamentous fungi such as, e.g., *Neurospora*, *Penicillium*, *Tolypocladium* (WO 91/00357 published 10 January 1991), and *Aspergillus* hosts such as *A. nidulans* (Ballance et al., *Biochem. Biophys. Res. Commun.* 112:284-289 [1983]; Tilburn et al., *Gene* 26:205-221 [1983]; Yelton et al., *Proc. Natl. Acad. Sci. USA* 81:1470-1474 [1984]) and *A. niger* (Kelly and Hynes, *EMBO J.* 4:475-479 [1985]).

35 Suitable host cells for the expression of glycosylated heteromultimer are derived from multicellular organisms. Such host cells are capable of complex processing and glycosylation activities. In principle, any higher eukaryotic cell culture is workable, whether from vertebrate or invertebrate culture. Examples of invertebrate cells include plant and 40 insect cells. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as *Spodoptera frugiperda* (caterpillar), *Aedes aegypti* (mosquito), *Aedes albopictus* (mosquito), *Drosophila melanogaster* (fruitfly), and *Bombyx mori* have been identified. See, e.g., Luckow et al., *Bio/Technology* 6:47-55 (1988); Miller et al., in 45 *Genetic Engineering*, Setlow et al., eds., Vol. 8 (Plenum Publishing, 1986), pp. 277-279; and Maeda et al., *Nature* 315:592-594 (1985). A variety of

viral strains for transfection are publicly available, e.g., the L-1 variant of *Autographa californica* NPV and the Bm-5 strain of *Bombyx mori* NPV, and such viruses may be used as the virus herein according to the present invention, particularly for transfection of *Spodoptera frugiperda* cells.

Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco can be utilized as hosts. Typically, plant cells are transfected by incubation with certain strains of the bacterium *Agrobacterium tumefaciens*, which has been previously manipulated to contain the heteromultimer DNA. During incubation of the plant cell culture with *A. tumefaciens*, the DNA encoding the heteromultimer is transferred to the plant cell host such that it is transfected, and will, under appropriate conditions, express the heteromultimer DNA. In addition, regulatory and signal sequences compatible with plant cells are available, such as the nopaline synthase promoter and polyadenylation signal sequences. Depicker et al., J. Mol. Appl. Gen. 1:561 (1982). In addition, DNA segments isolated from the upstream region of the T-DNA 780 gene are capable of activating or increasing transcription levels of plant-expressible genes in recombinant DNA-containing plant tissue. EP 321,196 published 21 June 1989.

The preferred hosts are vertebrate cells, and propagation of vertebrate cells in culture (tissue culture) has become a routine procedure in recent years (Tissue Culture, Academic Press, Kruse and Patterson, editors [1973]). Examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen. Virol. 36:59 [1977]); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA 77:4216 [1980]); mouse sertoli cells (TM4, Mather, Biol. Reprod. 23:243-251 [1980]); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (WI38, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals N.Y. Acad. Sci. 383:44-68 [1982]); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2).

Host cells are transfected with the above-described expression or cloning vectors of this invention and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. Depending on the host cell used, transfection is done using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in section 1.82 of Sambrook et al., *supra*, or electroporation is generally used for prokaryotes or other cells that contain substantial cell-wall barriers. Infection with *Agrobacterium*

tumefaciens is used for transformation of certain plant cells, as described by Shaw et al., Gene 23:315 (1983) and WO 89/05859 published 29 June 1989. In addition, plants may be transfected using ultrasound treatment as described in WO 91/00358 published 10 January 1991.

5 For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virology 52:456-457 (1978) is preferred. General aspects of mammalian cell host system transformations have been described by Axel in U.S. Patent No. 4,399,216 issued 16 August 1983. Transformations into yeast are typically carried  
10 out according to the method of Van Solingen et al., J. Bact. 130:946 (1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA) 76:3829 (1979). However, other methods for introducing DNA into cells, such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, e.g., polybrene, polyornithine, etc., may also be  
15 used. For various techniques for transforming mammalian cells, see Keown et al., Methods in Enzymology (1989), Keown et al., Methods in Enzymology 185:527-537 (1990), and Mansour et al., Nature 336:348-352 (1988).

20 Prokaryotic cells used to produce the heteromultimer polypeptide of this invention are cultured in suitable media as described generally in Sambrook et al., *supra*.

The mammalian host cells used to produce the heteromultimer of this invention may be cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ([MEM], Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ([DMEM], Sigma)  
25 are suitable for culturing the host cells. In addition, any of the media described in Ham and Wallace, Meth. Enz. 58:44 (1979), Barnes and Sato, Anal. Biochem. 102:255 (1980), U.S. Patent Nos. 4,767,704; 4,657,866; 4,927,762; or 4,560,655; WO 90/03430; WO 87/00195; U.S. Patent Re. 30,985; or U.S. Patent No. 5,122,469, the disclosures of all of which are  
30 incorporated herein by reference, may be used as culture media for the host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleosides (such as adenosine and thymidine), antibiotics (such as Gentamycin™ drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations  
35 that would be known to those skilled in the art. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

In general, principles, protocols, and practical techniques for maximizing the productivity of mammalian cell cultures can be found in  
45 Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed., IRL Press, 1991.

The host cells referred to in this disclosure encompass cells in culture as well as cells that are within a host animal.

4. Recovery of the Heteromultimer

The heteromultimer preferably is generally recovered from the culture medium as a secreted polypeptide, although it also may be recovered from host cell lysate when directly produced without a secretory signal. If the heteromultimer is membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g. Triton-X 100)

When the heteromultimer is produced in a recombinant cell other than one of human origin, it is completely free of proteins or polypeptides of human origin. However, it is necessary to purify the heteromultimer from recombinant cell proteins or polypeptides to obtain preparations that are substantially homogeneous as to heteromultimer. As a first step, the culture medium or lysate is normally centrifuged to remove particulate cell debris.

Heterodimers having antibody constant domains can be conveniently purified by hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography, with affinity chromatography being the preferred purification technique. Where the heteromultimer comprises a C<sub>h</sub>3 domain, the Bakerbond ABX™ resin (J. T. Baker, Phillipsburg, NJ) is useful for purification. Other techniques for protein purification such as fractionation on an ion-exchange column, ethanol precipitation, reverse phase HPLC, chromatography on silica, chromatography on heparin Sepharose, chromatography on an anion or cation exchange resin (such as a polyaspartic acid column), chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation are also available depending on the polypeptide to be recovered. The suitability of protein A as an affinity ligand depends on the species and isotype of the immunoglobulin Fc domain that is used in the chimera. Protein A can be used to purify immunoadhesins that are based on human  $\gamma$ 1,  $\gamma$ 2, or  $\gamma$ 4 heavy chains (Lindmark et al., J. Immunol. Meth. 62:1-13 [1983]). Protein G is recommended for all mouse isotypes and for human  $\gamma$ 3 (Guss et al., EMBO J. 5:15671575 [1986]). The matrix to which the affinity ligand is attached is most often agarose, but other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be achieved with agarose. The conditions for binding an immunoadhesin to the protein A or G affinity column are dictated entirely by the characteristics of the Fc domain; that is, its species and isotype. Generally, when the proper ligand is chosen, efficient binding occurs directly from unconditioned culture fluid. One distinguishing feature of immunoadhesins is that, for human  $\gamma$ 1 molecules, the binding capacity for protein A is somewhat diminished relative to an antibody of the same Fc type. Bound immunoadhesin can be efficiently eluted either at acidic pH (at or above 3.0), or in a neutral pH buffer containing a mildly

chaotropic salt. This affinity chromatography step can result in a heterodimer preparation that is >95% pure.

5. Uses for the Heteromultimer

Many therapeutic applications for the heteromultimer are contemplated. For example, the heteromultimer can be used for redirected cytotoxicity (e.g. to kill tumor cells), as a vaccine adjuvant, for delivering thrombolytic agents to clots, for delivering immunotoxins to tumor cells, for converting enzyme activated prodrugs at a target site (e.g. a tumor), for treating infectious diseases or targeting immune complexes to cell surface receptors.

Therapeutic formulations of the heteromultimer are prepared for storage by mixing the heteromultimer having the desired degree of purity with optional physiologically acceptable carriers, excipients, or stabilizers (Remington's Pharmaceutical Sciences, 16th edition, Osol, A., Ed., [1980]), in the form of lyophilized cake or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, Pluronics or polyethylene glycol (PEG).

The heteromultimer also may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (for example, hydroxymethylcellulose or gelatin-microcapsules and poly-[methylmethacrylate] microcapsules, respectively), in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules), or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, supra.

The heteromultimer to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution. The heteromultimer ordinarily will be stored in lyophilized form or in solution.

Therapeutic heteromultimer compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

The route of heteromultimer administration is in accord with known methods, e.g., injection or infusion by intravenous, intraperitoneal,

intracerebral, intramuscular, intraocular, intraarterial, or intralesional routes, or by sustained release systems as noted below. The heteromultimer is administered continuously by infusion or by bolus injection.

Suitable examples of sustained-release preparations include  
5 semipermeable matrices of solid hydrophobic polymers containing the protein, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels [e.g., poly(2-hydroxyethyl-methacrylate) as described by Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981) and Langer, 10 Chem. Tech. 12:98-105 (1982) or poly(vinylalcohol)], polylactides (U.S. Patent No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., Biopolymers 22:547-556 [1983]), non-degradable ethylene-vinyl acetate (Langer et al., *supra*), degradable lactic acid-glycolic acid copolymers such as the Lupron Depot™ (injectable 15 microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid (EP 133,988).

While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain 20 hydrogels release proteins for shorter time periods. When encapsulated proteins remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational 25 strategies can be devised for protein stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulphydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix 30 compositions.

Sustained-release heteromultimer compositions also include liposomally entrapped heteromultimer. Liposomes containing heteromultimer are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; 35 EP 142,641; Japanese patent application 83-118008; U.S. Patent Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. % cholesterol, the selected 40 proportion being adjusted for the optimal heteromultimer therapy.

An effective amount of heteromultimer to be employed therapeutically will depend, for example, upon the therapeutic objectives, the route of administration, and the condition of the patient. Accordingly, it will be necessary for the therapist to titer the dosage and modify the route of 45 administration as required to obtain the optimal therapeutic effect. A typical daily dosage might range from about 1 µg/kg to up to 10 mg/kg or

more, depending on the factors mentioned above. Typically, the clinician will administer heteromultimer until a dosage is reached that achieves the desired effect. The progress of this therapy is easily monitored by conventional assays.

5 The heteromultimers described herein can also be used in enzyme immunoassays. To achieve this, one arm of the heteromultimer can be designed to bind to a specific epitope on the enzyme so that binding does not cause enzyme inhibition, the other arm of the heteromultimer can be designed to bind to the immobilizing matrix ensuring a high enzyme density  
10 at the desired site. Examples of such diagnostic heteromultimers include those having specificity for IgG as well as ferritin, and those having binding specificities for horse radish peroxidase (HRP) as well as a hormone, for example.

The heteromultimers can be designed for use in two-site immunoassays.  
15 For example, two bispecific heteromultimers are produced binding to two separate epitopes on the analyte protein - one heteromultimer binds the complex to an insoluble matrix, the other binds an indicator enzyme.

Heteromultimers can also be used for in vitro or in vivo immunodiagnosis of various diseases such as cancer. To facilitate this  
20 diagnostic use, one arm of the heteromultimer can be designed to bind a tumor associated antigen and the other arm can bind a detectable marker (e.g. a chelator which binds a radionuclide). For example, a heteromultimer having specificities for the tumor associated antigen CEA  
25 as well as a bivalent hapten can be used for imaging of colorectal and thyroid carcinomas. Other non-therapeutic, diagnostic uses for the heteromultimer will be apparent to the skilled practitioner.

For diagnostic applications, at least one arm of the heteromultimer typically will be labeled directly or indirectly with a detectable moiety. The detectable moiety can be any one which is capable of producing, either  
30 directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ , or  $^{125}\text{I}$ ; a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin; or an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase (HRP).

35 Any method known in the art for separately conjugating the heteromultimer to the detectable moiety may be employed, including those methods described by Hunter et al., Nature 144:945 (1962); David et al., Biochemistry 13:1014 (1974); Pain et al., J. Immunol. Meth. 40:219 (1981); and Nygren, J. Histochem. and Cytochem. 30:407 (1982).

40 The heteromultimers of the present invention may be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays. Zola, Monoclonal Antibodies; A Manual of Techniques, pp.147-158 (CRC Press, Inc., 1987).

45 Competitive binding assays rely on the ability of a labeled standard to compete with the test sample analyte for binding with a limited amount of heteromultimer. The amount of analyte in the test sample is inversely

proportional to the amount of standard that becomes bound to the heteromultimer. To facilitate determining the amount of standard that becomes bound, the heteromultimers generally are insolubilized before or after the competition, so that the standard and analyte that are bound to the heteromultimers may conveniently be separated from the standard and analyte which remain unbound.

The heteromultimers are particularly useful for sandwich assays which involve the use of two molecules, each capable of binding to a different immunogenic portion, or epitope, of the sample to be detected. In a sandwich assay, the test sample analyte is bound by a first arm of the heteromultimer which is immobilized on a solid support, and thereafter a second arm of the heteromultimer binds to the analyte, thus forming an insoluble three part complex. See, e.g., US Pat No. 4,376,110. The second arm of the heteromultimer may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assay). For example, one type of sandwich assay is an ELISA assay, in which case the detectable moiety is an enzyme.

Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

All publications, patents and patent applications cited herein, whether *supra* or *infra*, are hereby incorporated by reference in their entirety.

#### EXAMPLES

The C<sub>h</sub>3 interface between the humanized anti-CD3/CD4-IgG chimera previously described by Chamow et al. *J. Immunol.* 153:4268 (1994) was engineered to maximize the percentage of heteromultimers which could be recovered. Protuberance-into-cavity and wild-type C<sub>h</sub>3 variants were compared in their ability to direct the formation of a humanized antibody-immunoadhesin chimera (Ab/Ia) anti-CD3/CD4-IgG.

Thus, mutations were constructed in the C<sub>h</sub>3 domain of the humanized anti-CD3 antibody heavy chain and in CD4-IgG by site-directed mutagenesis using mismatched oligonucleotides (Kunkel et al., *Methods Enzymol.* 154: 367 [1987] and P. Carter, in *Mutagenesis: a Practical Approach*, M. J. McPherson, Ed., IRL Press, Oxford, UK, pp. 1-25 [1991]) and verified by dideoxynucleotide sequencing (Sanger et al., *Proc. Natl. Acad. Sci. USA* 74: 5463 [1977]). See Table 4 below and Fig. 7 herein.

40

TABLE 4

Most Preferred Mutants	
C <sub>h</sub> 3 of anti-CD3	C <sub>h</sub> 3 of CD4-IgG
T366Y	Y407T

5

T366W	Y407A
F405A	T394W
Y407T	T366Y
T366Y:F405A	T394W:Y407T
T366W:F405W	T394S:Y407A
F405W:Y407A	T366W:T394S

Preferred Mutants	
F405W	T394S

Residue T366 is within hydrogen-bonding distance of residue Y407 on 10 the partner C<sub>H</sub>3 domain. Indeed the principal intermolecular contact to residue T366 is to residue Y407 and vice versa. One protuberance-into-cavity pair was created by inverting these residues with the reciprocal mutations of T366Y in one C<sub>H</sub>3 domain and Y407T in the partner domain thus maintaining the volume of side chains at the interface (Fig. 9). Mutations 15 are denoted by the wild-type residue followed by the position using the Kabat numbering system (Kabat et al., *Sequences of Proteins of Immunological Interest*, National Institutes of Health, Bethesda, MD, ed. 5, [1991]) and then the replacement residue in single-letter code. Multiple mutations are denoted by listing component single mutations 20 separated by a colon.

Phagemids encoding anti-CD3 light (L) and heavy (H) chain variants (Shalaby et al., *J. Exp. Med.* 175: 217 [1992] and Rodrigues et al., *Int. J. Cancer (Suppl.)* 7: 45 [1992]) were co-transfected into human embryonic kidney cells, 293S, together with a CD4-IgG variant encoding phagemid (Byrn 25 et al., *Nature* 344: 667 [1990]) as previously described (Chamow et al., *J. Immunol.* 153: 4268 [1994]). The procedure is illustrated in Fig. 8 herein. The total amount of transfected phagemid DNAs was fixed whereas the ratio of different DNAs was varied to maximize the yield of Ab/Ia chimera. The ratio (by mass) of Ia : H chain : L chain input DNAs (15 µg total) was 30 varied as follows: 8:1:3; 7:1:3; 6:1:3; 5:1:3; 4:1:3; 3:1:3; 1:0:0; 0:1:3.

The products were affinity purified using Staphylococcal protein A (ProSep A, BioProcessing Ltd, UK) prior to analysis by SDS-PAGE followed by scanning LASER densitometry (Figs. 10A-10E). Excess L over H chain DNA was used to avoid the L chain from being limiting. The identity of 35 products was verified by electroblotting on to PVDF membrane (Matsudaira, *J. Biol. Chem.* 262: 10035 [1987]) followed by amino terminal sequencing.

Co-transfection of phagemids for L chain together with those for H chain and Ia incorporating wild-type C<sub>H</sub>3 resulted in a mixture of Ab/Ia chimera, IgG and Ia homodimer products as expected (Chamow et al., *J. Immunol.* 153: 4268 [1994]). See Fig. 10A. The larger the fraction of 40 input DNA encoding antibody H plus L chains or Ia the higher the fraction

of corresponding homodimers recovered. An input DNA ratio of 6:1:3 of Ia:H:L yielded 54.5 % Ab/Ia chimera with similar fractions of Ia homodimer (22.5 %) and IgG (23.0 %). These ratios are in good agreement with those expected from equimolar expression of each chain followed by random 5 assortment of H chains with no bias being introduced by the method of analysis: 50 % Ab/Ia chimera, 25 % Ia homodimer and 25 % IgG.

In contrast to chains containing wild-type C<sub>h</sub>3, Ab/Ia chimera was recovered in yields of up to 92 % from cotransfections in which the anti-CD3 H chain and CD4-IgG Ia contained the Y407T cavity and T366Y protuberance mutations, respectively (Fig. 10B). Similar yields of Ab/Ia chimera were obtained if these reciprocal mutations were installed with the protuberance on the H chain and the cavity in the Ia (Fig. 10C). In both cases monomer was observed for the chain containing the protuberance but not the cavity. Without being limited to any one theory, it is believed 10 that the T366Y protuberance is more disruptive to homodimer formation than the Y407T cavity. The fraction of Ab/Ia hybrid was not significantly changed by increasing the size of both protuberance and cavity (Ab T366W, Ia Y407A). A second protuberance and cavity pair (Ab F405A, Ia T394W) 15 yielded up to 71 % Ab/Ia chimera using a small fraction of Ia input DNA to offset the unanticipated proclivity of the Ia T394W protuberance variant to homodimerize (Fig. 10D). Combining the two independent protuberance-into-cavity mutant pairs (Ab T366Y:F405A, Ia T394W:Y407T) did not improve 20 the yield of Ab/Ia hybrid over the Ab T366Y, Ia Y407T pair (compare Fig. 10C and 10E).

The fraction of Ab/Ia chimera obtained with T366Y and Y407T mutant 25 pair was virtually independent of the ratio of input DNAs over the range tested. Furthermore the contaminating species were readily removed from the Ab/Ia chimera by ion exchange chromatography (0-300 mM NaCl in 20 mM Tris-HCl, pH8.0) on a mono S HR 5/5 column (Pharmacia, Piscataway, NJ). This augurs well for the preparation of larger quantities Ab/Ia chimeras 30 using stable cell lines where the relative expression levels of Ab and Ia are less readily manipulated than in the transient expression system.

The protuberance-into-cavity mutations identified are anticipated to increase the potential applications of Fc-containing BsAb by reducing the 35 complexity of the mixture of products obtained from a possible ten major species (Suresh et al., *Methods Enzymol.* 121: 210 [1990]) down to four or less. It is expected that the T366Y and Y407T mutant pair will be useful for generating heteromultimers of other human IgG isotypes since T366 and 40 Y407 are fully conserved and other residues at the C<sub>h</sub>3 domain interface of IgG, are highly conserved (see Fig. 6 herein).

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

5 (i) APPLICANT: Genentech, Inc.

(ii) TITLE OF INVENTION: A METHOD FOR MAKING HETEROMULTIMERIC POLYPEPTIDES

10 (iii) NUMBER OF SEQUENCES: 16

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Genentech, Inc.  
 (B) STREET: 460 Point San Bruno Blvd  
 (C) CITY: South San Francisco  
 (D) STATE: California  
 (E) COUNTRY: USA  
 (F) ZIP: 94080

20 (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: 3.5 inch, 720 Kb floppy disk  
 (B) COMPUTER: IBM PC compatible  
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS  
 (D) SOFTWARE: WinPatin (Genentech)

25 (vi) CURRENT APPLICATION DATA:  
 (A) APPLICATION NUMBER:  
 (B) FILING DATE: 05-Feb-1996  
 (C) CLASSIFICATION:

30 (vii) PRIOR APPLICATION DATA:  
 (A) APPLICATION NUMBER: 08/399106  
 (B) FILING DATE: 01-MAR-1995

35 (viii) ATTORNEY/AGENT INFORMATION:  
 (A) NAME: Lee, Wendy M.  
 (B) REGISTRATION NUMBER: 00,000  
 (C) REFERENCE/DOCKET NUMBER: P0927PCT

40 (ix) TELECOMMUNICATION INFORMATION:  
 (A) TELEPHONE: 415/225-1994  
 (B) TELEFAX: 415/952-9881  
 (C) TELEX: 910/371-7168

45 (2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 108 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg
55	341				345				350					355	
	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys
			360						365					370	
60	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Asp
							375		380					385	
	Gly	Glx	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp
					390				395					400	
65	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys
							405		410					415	

Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His  
 420 425 430  
 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser  
 5 435 440 445  
 Pro Gly Lys  
 448

## 10 (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 108 amino acids
- (B) TYPE: Amino Acid
- (C) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg
20	341			345				350			355			

Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys
	360							365				370		

Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Asp
25									375		380		385	

Gly	Glx	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Met	Leu	Asp
								390		395		400		

Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys
30								405		410		415		

Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His
35								420		425		430		

Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser
								435		440		445		

Pro	Gly	Lys												
40		448												

## (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 108 amino acids
- (B) TYPE: Amino Acid
- (C) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg
45	341			345				350			355			

Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys
50								360		365		370		

Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Asp
								375		380		385		

Gly	Glx	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp
60								390		395		400		

Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Arg	Leu	Thr	Val	Asp	Lys
65								405		410		415		

Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His
								420		425		430		

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser  
 435 440 445

5 Pro Gly Lys  
 448

## (2) INFORMATION FOR SEQ ID NO:4:

10 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 113 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Gly Asn Thr Phe Arg Pro Gln Val His Leu Leu Pro Pro Pro Ser  
 341 345 350 355

20 Glu Glu Leu Ala Leu Asx Glx Leu Val Thr Leu Thr Cys Leu Ala  
 360 365 370

Arg Gly Phe Ser Pro Lys Asp Val Leu Val Arg Trp Leu Gln Gly  
 375 380 385

25 Ser Gln Glu Leu Pro Arg Glu Lys Tyr Leu Thr Trp Ala Ser Arg  
 390 395 400

Gln Glx Pro Ser Gln Gly Thr Thr Phe Ala Val Thr Ser Ile  
 405 410 415

30 Leu Arg Val Ala Ala Glu Asp Trp Lys Lys Gly Asp Thr Phe Ser  
 420 425 430

Cys Met Val Gly His Glu Ala Leu Pro Leu Ala Phe Thr Gln Lys  
 435 440 445

Thr Ile Asp Arg Leu Ala Gly Lys  
 450 453

## 40 (2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 107 amino acids  
 (B) TYPE: Amino Acid  
 45 (D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

50 Gln Ala Pro Val Lys Leu Ser Leu Asn Leu Leu Ala Ser Ser Asp  
 341 345 350 355

Pro Pro Glu Ala Ala Ser Trp Leu Leu Cys Glu Val Ser Gly Phe  
 360 365 370

55 Ser Pro Pro Asn Ile Leu Leu Met Trp Leu Glu Asp Gln Arg Glu  
 375 380 385

Val Asn Thr Ser Gly Phe Ala Pro Ala Arg Pro Pro Pro Gln Pro  
 390 395 400

60 Gly Ser Thr Thr Phe Trp Ala Trp Ser Val Leu Arg Val Pro Ala  
 405 410 415

65 Pro Pro Ser Pro Gln Pro Ala Thr Tyr Thr Cys Val Val Ser His  
 420 425 430

Glu Asp Ser Arg Thr Leu Leu Asn Ala Ser Arg Ser Leu Glu Val  
 435 440 445

Ser Tyr  
447

## (2) INFORMATION FOR SEQ ID NO:6:

5

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 110 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

10

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Gly Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu  
341 345 350 355

15

Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln  
360 365 370

20

Asn Phe Met Pro Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu  
375 380 385

25

Val Gln Leu Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys  
390 395 400

Arg Ala Glu Trp Glu Gln Lys Asp Glu Phe Ile Cys Arg Ala Val  
420 425 430

His Glu Ala Ala Ser Pro Ser Gln Thr Val Gln Arg Ala Val Ser  
435 440 445

Val Asn Pro Gly Lys  
450

## (2) INFORMATION FOR SEQ ID NO:7:

40

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 106 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Asp Glx Asx Thr Ala Ile Arg Val Phe Ala Ile Pro Pro Ser Phe  
342 345 350 355

50

Ala Ser Ile Phe Leu Thr Lys Ser Thr Lys Leu Thr Cys Leu Val  
360 365 370

60

Thr Asp Leu Thr Thr Tyr Asx Ser Val Thr Ile Ser Trp Thr Arg  
375 380 385

55

Glx Asp Gly Glu Ala Val Lys Thr His Thr Asx Ile Ser Glx Ser  
390 395 400

His Pro Asx Ala Thr Phe Ser Ala Val Gly Glu Ala Ser Ile Cys  
405 410 415

65

Glu Asx Asx Trp Asx Ser Gly Glu Arg Phe Thr Cys Thr Val Thr  
420 425 430

His Thr Asp Leu Pro Ser Pro Leu Lys Gln Thr Ile Ser Arg Pro  
435 440 445

Lys  
447

## (2) INFORMATION FOR SEQ ID NO:8:

## (i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 108 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

10	Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg			
	361	365	370	375
	Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys			
15	380	385	390	
	Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asx Asp			
	395	400	405	
20	Gly Glx Pro Glx Asx Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp			
	410	415	420	
	Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys			
	425	430	435	
25	Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His			
	440	445	450	
	Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser			
30	455	460	465	
	Pro Gly Lys			
	468			

## (2) INFORMATION FOR SEQ ID NO:9:

## (i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 107 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

40	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:			
	Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg			
45	361	365	370	375
	Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys			
	380	385	390	
50	Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly			
	395	400	405	
	Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser			
	410	415	420	
55	Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser			
	425	430	435	
	Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu			
60	440	445	450	
	Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro			
	455	460	465	
65	Gly Lys			
	467			

## (2) INFORMATION FOR SEQ ID NO:10:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 107 amino acids
- (B) TYPE: Amino Acid
- (C) TOPOLOGY: Linear

5

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Gly Gln Pro Arg Glx Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg			
361	365	370	375
Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys			
380		385	390
Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Ser Gly			
15	395	400	405
Gln Pro Glu Asn Asn Tyr Asn Thr Thr Pro Pro Met Leu Asp Ser			
410		415	420
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser			
20	425	430	435
Arg Trp Gln Gln Gly Asn Ile Phe Ser Cys Ser Val Met His Glu			
440		445	450
Ala Leu His Asn Arg Phe Thr Gln Lys Ser Leu Ser Leu Ser Pro			
25	455	460	465
Gly Lys			
30	467		

## (2) INFORMATION FOR SEQ ID NO:11:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 107 amino acids
- (B) TYPE: Amino Acid
- (C) TOPOLOGY: Linear

40

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln			
361	365	370	375
Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys			
380		385	390
Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glx Ser Asn Gly			
395	400	405	
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser			
50	410	415	420
Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser			
425		430	435
Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu			
55	440	445	450
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu			
60	455	460	465
Gly Lys			
65	467		

## (2) INFORMATION FOR SEQ ID NO:12:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 107 amino acids

(B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro Pro Lys  
 361 365 370 375  
 10 Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr  
     380 385 390  
 Asp Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp Asx Gly  
     395 400 405  
 15 Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asx Thr  
     410 415 420  
 Asx Gly Ser Tyr Phe Val Tyr Ser Lys Leu Asn Val Gln Lys Ser  
 20 425 430 435  
 Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu  
     440 445 450  
 25 Gly Leu His Asn His His Thr Glu Lys Ser Leu Ser His Ser Pro  
     455 460 465  
 Gly Lys  
     467

30 (2) INFORMATION FOR SEQ ID NO:13:

35 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 107 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Gly Pro Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Ala  
 40 361 365 370 375  
 Glu Glu Met Thr Lys Lys Glx Phe Ser Leu Thr Cys Met Ile Thr  
     380 385 390  
 45 Gly Phe Leu Pro Ala Glu Ile Ala Val Glu Trp Thr Ser Asn Gly  
     395 400 405  
 Arg Thr Glu Gln Asn Tyr Lys Asn Thr Ala Thr Val Leu Asp Ser  
 50 410 415 420  
 Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glx Lys Ser  
     425 430 435  
 55 Thr Trp Glu Arg Gly Ser Leu Phe Ala Cys Ser Val Val His Glu  
     440 445 450  
 Gly Leu His Asn His Leu Thr Thr Lys Thr Phe Ser Arg Ser Leu  
     455 460 465  
 60 Gly Lys  
     467

(2) INFORMATION FOR SEQ ID NO:14:

65 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 107 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Gly Leu Val Arg Ala Pro Gln Val Tyr Thr Leu Pro Pro Pro Ala  
 361 365 370 375  
 5 Glu Gln Leu Ser Arg Lys Asp Val Ser Leu Thr Cys Leu Val Val  
 380 385 390  
 Gly Phe Asn Pro Gly Asp Ile Ser Val Glu Trp Thr Ser Asn Gly  
 10 395 400 405  
 His Thr Glu Glu Asn Tyr Lys Asx Thr Ala Pro Val Leu Asp Ser  
 410 415 420  
 15 Asp Gly Ser Tyr Phe Ile Tyr Ser Lys Leu Asn Met Lys Thr Ser  
 425 430 435  
 Lys Trp Glu Lys Thr Asp Ser Phe Ser Cys Asn Val Arg His Glu  
 440 445 450  
 20 Gly Leu Lys Asn Tyr Tyr Leu Lys Lys Thr Ile Ser Arg Ser Pro  
 455 460 465  
 25 Gly Lys  
 467

## (2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:  
 30 (A) LENGTH: 107 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

35 Gly Arg Ala Gln Thr Pro Gln Val Tyr Thr Ile Pro Pro Pro Arg  
 361 365 370 375  
 Glu Gln Met Ser Lys Lys Lys Val Ser Leu Thr Cys Leu Val Thr  
 40 380 385 390  
 Asn Phe Phe Ser Glu Ala Ile Ser Val Glu Trp Glu Arg Asn Gly  
 395 400 405  
 45 Glu Leu Glu Gln Asp Tyr Lys Asn Thr Pro Pro Ile Leu Asp Ser  
 410 415 420  
 Asp Gly Thr Tyr Phe Leu Tyr Ser Lys Leu Thr Val Asp Thr Asp  
 425 430 435  
 50 Ser Trp Leu Gln Gly Glu Ile Phe Thr Cys Ser Val Val His Glu  
 440 445 450  
 Ala Leu His Asn His His Thr Gln Lys Asn Leu Ser Arg Ser Pro  
 455 460 465  
 Gly Lys  
 467

## 60 (2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:  
 65 (A) LENGTH: 29 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

5           Lys Asp Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro  
        451                 455                 460                 465  
         Ser Gln Thr Val Gln Arg Ala Val Ser Val Asn Pro Gly Lys  
        470                 475                 479

## CLAIMS:

1. A method of preparing a heteromultimer comprising a first polypeptide and a second polypeptide which meet at an interface, wherein the interface of the first polypeptide comprises a protuberance which is positionable in a cavity in the interface of the second polypeptide, the method comprising the steps of:
  - (a) culturing a host cell comprising nucleic acid encoding the first polypeptide and second polypeptide, wherein the nucleic acid encoding the first polypeptide has been altered from the original nucleic acid to encode the protuberance or the nucleic acid encoding the second polypeptide has been altered from the original nucleic acid to encode the cavity, or both, and wherein the culturing is such that the nucleic acid is expressed; and
  - (b) recovering the heteromultimer from the host cell culture.
- 15 2. The method of claim 1 wherein the nucleic acid encoding the first polypeptide has been altered from the original nucleic acid to encode the protuberance and the nucleic acid encoding the second polypeptide has been altered from the original nucleic acid to encode the cavity.
- 20 3. The method of claim 1 wherein step (a) is preceded by a step wherein nucleic acid encoding an original residue from the interface of the first polypeptide is replaced with nucleic acid encoding an import residue having a larger side chain volume than the original residue.
- 25 4. The method of claim 3 wherein the import residue is arginine (R).
5. The method of claim 3 wherein the import residue is phenylalanine (F).
- 30 6. The method of claim 3 wherein the import residue is tyrosine (Y).
7. The method of claim 3 wherein the import residue is tryptophan (W).
- 35 8. The method of claim 1 wherein step (a) is preceded by a step wherein nucleic acid encoding an original residue in the interface of the second polypeptide is replaced with nucleic acid encoding an import residue having a smaller side chain volume than the original residue.
- 40 9. The method of claim 8 wherein the import residue is not cysteine (C).
10. The method of claim 8 wherein the import residue is alanine (A).
- 45 11. The method of claim 8 wherein the import residue is serine (S).

12. The method of claim 8 wherein the import residue is threonine (T).

13. The method of claim 8 wherein the import residue is valine (V).  
5

14. The method of claim 1 wherein the first and second polypeptide each comprise an antibody constant domain.

15. The method of claim 14 wherein the antibody constant domain is  
10 a C<sub>h</sub>3 domain.

16. The method of claim 15 wherein the antibody constant domain is from an IgG.

15 17. The method of claim 16 wherein the IgG is human IgG<sub>1</sub>.

18. The method of claim 1 wherein the heteromultimer is a bispecific antibody.

20 19. The method of claim 1 wherein the heteromultimer is a bispecific immunoadhesin.

20. The method of claim 1 wherein the heteromultimer is an antibody-immunoadhesin chimera.

25 21. The method of claim 3 wherein one original residue from the first polypeptide has been replaced with an import residue.

30 22. The method of claim 8 wherein one original residue from the second polypeptide has been replaced with an import residue.

23. The method of claim 1 wherein step (a) is preceded by a step wherein the nucleic acid encoding the first and second polypeptide is introduced into the host cell.

35 24. A heteromultimer prepared by the method of claim 1.

25. A heteromultimer comprising a first polypeptide and a second polypeptide which meet at an interface, wherein the interface of the first 40 polypeptide comprises a protuberance which is positionable in a cavity in the interface of the second polypeptide, and wherein the protuberance or cavity, or both, have been introduced into the interface of the first and second polypeptides respectively.

26. The heteromultimer of claim 25 wherein the protuberance and cavity have been introduced into the interface of the first and second polypeptides respectively.

5 27. The heteromultimer of claim 26 wherein the protuberance and cavity each comprise a naturally occurring amino acid residue.

28. A composition comprising the heteromultimer of claim 25 and a pharmaceutically acceptable carrier.

10

29. A host cell comprising nucleic acid encoding the heteromultimer of claim 25.

15 30. The host cell of claim 29 wherein the nucleic acid encoding the first polypeptide and the nucleic acid encoding the second polypeptide are present in a single vector.

20 31. The host cell of claim 29 wherein the nucleic acid encoding the first polypeptide and the nucleic acid encoding the second polypeptide are present in separate vectors.

32. A method of making a heteromultimer comprising culturing the host cell of claim 29 so that the nucleic acid is expressed and recovering the heteromultimer from the cell culture.

25

33. The method of claim 32 wherein the host cell is a mammalian cell.

34. The method of claim 32 wherein the heteromultimer is recovered from the cell culture media.

30

35. A method of preparing a heteromultimer comprising:

(a) altering a first nucleic acid encoding a first polypeptide so that an amino acid residue in the interface of the first polypeptide is replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance on the first polypeptide;

(b) altering a second nucleic acid encoding a second polypeptide so that an amino acid residue in the interface of the second polypeptide is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity in the second polypeptide, wherein the protuberance is positionable in the cavity;

(c) introducing into a host cell the first and second nucleic acids and culturing the cell so that expression of the first and second nucleic acid occurs;











(d) recovering the heteromultimer formed from the cell culture.

45

36. The method of claim 35 wherein the first and second polypeptide each comprise an antibody constant domain.

37. The method of claim 35 wherein the antibody constant domain is  
5 a C<sub>ε</sub>3 domain.

38. The method of claim 37 wherein the antibody constant domain is from a human IgG.

**Monospecific Bivalent****Bispecific Monovalent****Monospecific Monovalent****"Inactive"****FIG. I**

2/11

BsF(ab')<sub>2</sub>  
CHEMICALLY COUPLED  
RODENT FRAGMENTS




FIG. 2A

BsF(ab')<sub>2</sub>  
CHEMICALLY COUPLED  
E. coli DERIVED FRAGMENTS




FIG. 2B

BsF(ab')<sub>2</sub>  
LEUCINE ZIPPER  
ASSEMBLED






FIG. 2C



sFv DIMER




FIG. 2E




DIABODY

FIG. 2D

3/11

**FIG. 3A****FIG. 3B****FIG. 3C**

4 / 11



Wild Type  
single mutants  
double mutants  
double mutants

FIG. 4

edge, interface

5/11

	B i B I B I      B i
IgG	G Q P R E P Q V Y T L P P S R E E M T K N Q
IgA	G N T F R P Q V H L L P P P S E E L A L B Z L
IgD	Q A P V K L S L N L L A S S D P - - P E A A
IgE	G P R A A P E V Y A F A T P E W P G S R D K
IgM	- D Z B T A I R V F A I P P S F A S I F L T K S
	350                    360

middle, interface

exterior

	B I B I B I B i	B    B    B
IgG	V S L T C L V K G F Y P S D I A V E W E S N	
IgA	V T L T C L A R G F S P K D V L V R W L Q G	
IgD	S W L L C E V S G F S P P N I L L M W L E D Q	
IgE	R T L A C L I Q N F M P E D I S V Q W L H N	
IgM	T K L T C L V T D L T T Y B S V T I S W T R Z	
	370                    380	

edge, interface

	I                i                I
IgG	D - G Q P E N N Y K T T P P V/M L D S D G S
IgA	S Q E L P R E K Y L T W A S R Q Z P S Q G T T T
IgD	R E V N T S G F A P A R P P P Q P G S T T
IgE	E V Q L P D A R H S T T Q P R K T K G S G
IgM	D - - G E A V K T H T B I S Z S H P B A T
	390                    400

middle, interface

exterior

	B I B I B I      B i B      B      B      B
IgG	F F L Y S K/R L T V D K S R W Q Q G N V F S C S V M
IgA	F A V T S I      L R V A A E D W K K G D T F S C M V G
IgD	F W A W S V      L R V P A P P S P Q P A T Y T C V V S
IgE	F F V F S R      L E V T R A E W E Q K D E F I C R A V
IgM	F S A V G E      A S I C E B B W B S G E R F T C T V T
	410                    420

exterior

	B                b                b
IgG	H E A L H N H Y T Q K S L S L S P G K
IgA	H E A L P L A F T Q K T I D R L A G K
IgD	H E D - S R T L L N A S R S L E V S Y
IgE	H E A A S P S Q T V Q R A V S V N P G K
IgM	H T D L P S P L K Q T I S R P K - - -
	430                    440

FIG. 5

6/11

		MIDDLE		
361	G - Q P R E P G - Q P R E Z G - Q P R E E G - Q P R E P	390 380 370 361	P P S R E E - - M T K N Q P P S R E E - - M T K N Q P P S R E E - - M T K N Q P P S R E E - - M T K N Q	T C T C T C T C
hIgG1	↓ T L	390	V S I L T V S I L T V S I L T V S I L T	
hIgG2	↓ Y Y T T T	390	V S I L T V S I L T V S I L T V S I L T	
hIgG3	↓ Q V V V V	390	V S I L T V S I L T V S I L T V S I L T	
hIgG4	↓ Q V V V V	390	V S I L T V S I L T V S I L T V S I L T	
mIgG1	↓ R P K A P G - P V R A P G - L V R A P G - R A Q T P	380	P P K E Q - - M A K D P P - A E E - M T K K P P - A E Q - L S R K P P - R E Q - M S K K	
mIgG2A	↓ G F Y P S mIgG2B	370	P P K E Q - - M A K D P P - A E E - M T K K P P - A E Q - L S R K P P - R E Q - M S K K	
mIgG3	↓ G F Y P S *****	370	P P K E Q - - M A K D P P - A E E - M T K K P P - A E Q - L S R K P P - R E Q - M S K K	
hIgG1	↓ I V K G F Y P S hIgG2	410	I A V E W E S - B D I A V E W E S - N G I A V E W E S - N G I A V E W E S - N G	
hIgG3	↓ I V K G F Y P S hIgG4	400	I V K G F Y P S I V K G F Y P S I V K G F Y P S I V K G F Y P S	
mIgG1	↓ M I T D F F P E mIgG2A	400	W Q T S - B G W Q T S - N G W Q T S - N G W Q T S - N G	
mIgG2B	↓ M I T G F F P A mIgG3	400	E W W T R - B G E W W T R - N G E W W T R - N G E W W T R - N G	
*****	*****	400	D I T V - - Q P A E D I T A V - - Q T E D I T S V - - H T E D I T S V - - E L E	

**FIG. 6A**

7/11

	EDGE	MIDDLE	430	450	460	470	480	
hIgG1	↓ P P P M L D	S - D -	↓ G S F F F F	D K S R W Q	G N T F T C S	G N T F T C S	G N T F T C S	
hIgG2	↓ T T T P P M L D	S - D -	- G S F F F F	D K S R W Q	S V L H E G L	S V L H E G L	S V L H E G L	
hIgG3	↓ T T T P P M L D	S - D -	- G S F F F F	D K S R W Q	V V H E G L	V V H E G L	V V H E G L	
hIgG4	↓ T T T P P P V L D	S - D -	- G S F F F F	D K S R W Q	R H E G L	R H E G L	R H E G L	
mIgG1	N T Q P I M B	T - B -	- G S Y F M Y S	K L N V Q K S N	H N H T E K S	H N H T E K S	H N H T E K S	
mIgG2A	N T A T V L D	S - D -	- G S Y F M Y S	Z T S K W E K	H N H T E K S	H N H T E K S	H N H T E K S	
mIgG2B	B T A P V L D	S - D -	- G S Y F M Y S	K T S K W E K	H N H T E K S	H N H T E K S	H N H T E K S	
mIgG3	N T P P I L D	S - D -	- G T Y F L Y S	D T D S W L Q	H N H T E K S	H N H T E K S	H N H T E K S	
*	*****	*****	*****	*****	*****	*****	*****	
451	hIgG1	G N V F S C S V M H E A L H N H Y T Q K S L S P G K	451	hIgG1	G N T F T C S V L H E G L H N H T E K S L S P G K	451	hIgG1	G N T F T C S V L H E G L H N H T E K S L S P G K
	hIgE	K D E F I C R A V H E A A S P S Q R A V S L V N P G K		hIgG2	G N V F S C S V M H E A L H N R F T Q K S L S P G K		hIgG2	G S L F A C S V V R H E G L H N Y L K T S R S P G K
	hIgG2	G N V F S C S V M H E A L H N R F T Q K S L S P G K		hIgG3	G N V F S C S V M H E A L H N H Y T Q K N L S R S P G K		hIgG3	G E T D S F C N V R H E G L K N Y L K T S R S P G K
	hIgG3	G N V F S C S V M H E A L H N H Y T Q K N L S R S P G K		hIgG4	G N V F S C S V M H E A L H N H Y T Q K N L S R S P G K		hIgG4	G N V F S C S V M H E A L H N H Y T Q K N L S R S P G K
*	*****	*****	*****	*	*****	*****	*****	*

FIG. 6B

8/11




FIG. 7

9/11





FIG. 8

10/11

FIG. 9



11/11

**FIG. 10A**




Ab/la

WT/WT

Y407T/T366Y

T366Y/Y407T

F405A/T394W

T366Y:F405A/  
T394W:Y407T**FIG. 10C****FIG. 10D****FIG. 10E**

## INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/US 96/01598

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/13 C07K16/46 C07K17/00 A61K39/395

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C07K C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,92 10209 (THE WISTRAL INSTITUTE OF ANATOMY AND BIOLOGY) 25 June 1992 see page 4, line 15 - page 6, line 7 see page 6, line 13 - page 12, line 7 see page 13, line 3 - page 18, line 22 ---	1-38
A	JOURNAL OF IMMUNOLOGY, vol. 151, no. 12, 15 December 1993, BALTIMORE US, pages 6954-6961, XP002007001 MARIA L. RODRIGUES ET AL.: "Engineering Fab' fragments for efficient F(ab)2 formation in Escherichia coli and for improved in vivo stability" see abstract see page 6955, left-hand column, paragraph 2 - page 1959, left-hand column, paragraph 1 -----	1-38

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*&\* document member of the same patent family

1

Date of the actual completion of the international search

28 June 1996

Date of mailing of the international search report

25.07.96

## Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax (+31-70) 340-3016

## Authorized officer

Montero Lopez, B

**INTERNATIONAL SEARCH REPORT**Int'l Application No  
PCT/US 96/01598

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9210209	25-06-92	CA-A-	2097060	05-06-92
		EP-A-	0563214	06-10-93
-----				